

**Arti Shukla**  
**Curriculum Vitae**

**Position:** Professor  
Department of Pathology and Laboratory Medicine

**Address:** Given D205  
Department of Pathology and Laboratory Medicine  
Larner College of Medicine, University of Vermont  
89 Beaumont Avenue  
Burlington, VT 05405  
(802) 656-8253  
[Arti.Shukla@med.uvm.edu](mailto:Arti.Shukla@med.uvm.edu)  
[http://contentmanager.med.uvm.edu/pathology/shukla-lab\\_new](http://contentmanager.med.uvm.edu/pathology/shukla-lab_new)

**EDUCATION**

<b>Year</b>	<b>Institution</b>	<b>Degree</b>	<b>Area of Degree</b>
1989	Banares Hindu University	PhD	Biochemistry
1985	Banares Hindu University	MS	Biochemistry
1982	Banares Hindu University	BS	Chemistry & Biology

**LICENSES AND CERTIFICATION:** None

**APPOINTMENTS HELD:**

<b>Years</b>	<b>Institution</b>	<b>Academic Title</b>	<b>Department</b>
January 2024-present	University of Vermont LCOM	Director, Path MS (Thesis track)	Department of Pathology
July 2020-present	University of Vermont Larner College of Medicine	Professor	Department of Pathology
July 2020-present	University of Vermont Larner College of Medicine	Professor (Secondary)	Department of Medicine
July 2011-2020	University of Vermont Larner College of Medicine	Associate Professor	Department of Pathology
August 2014 - 2020	University of Vermont Larner College of Medicine	Associate Professor (secondary)	Department of Medicine
December 2001- June 2011	University of Vermont Larner College of Medicine	Assistant Professor	Department of Pathology

October 1997- September 1999	University of Vermont Larner College of Medicine	Visiting Scientist	Departments of Pathology & Biochemistry
1991-1997	Central Drug Research Institute, Lucknow, India	Scientist	Department of Pharmacology
December 1988– November 1990	University of Michigan, Ann Arbor, MI	Post-doctoral Research Associate	Mental Health Research Institute
1985-1988	Institute of Medical Sciences, Banares Hindu University, Varanasi, India.	CSIR-Junior & CSIR- Senior Research Fellow	Department of Pediatrics

### **AWARDS AND HONORS**

<b>Year</b>	<b>Name of Award</b>
1985-1988	Junior and Senior Research Fellowship from Council of Scientific and Industrial Research, India
1987	Young Scientist Award from Nutrition Society of India
1991-1993	Pool Scientist Award from Council of Scientific and Industrial Research (CSIR), India
1996	Jyotsnamayee-Raghunath Award from Indian Academy of Neurosciences
1996	Unvas Award from Indian Pharmacological Society
2000	Best poster award in International Conference on Environmental and Occupational Lung Disease, hosted by Industrial Toxicology Research Centre, 29 October-2 November in Lucknow, India.
2004	Best poster award from Vermont Cancer Center
2005	Travel award from GeneSifter
2005	Co-chaired a scientific session in Mechanisms of Action of Inhaled Fibers, Particles and Nanoparticles in Lung and Cardiovascular Disease, held at EPA Conference Center, Research Triangle Park, NC from 26-28 Oct.
2008-2017	Received multiple (9) awards from internal sources (UVMCC, LCCRO, VGN, Surgery department, COM, UVM REACH)
2009-2012	Awarded Mesothelioma Applied Research Foundation grant to study role of ERK5 in mesothelioma

- 2016 The Department of Defense, Peer Reviewed Cancer Research Program (PRCRP) staff has highlighted our research in the 2016 PRCRP pages of the Congressionally Directed Medical Research Programs' Annual Report (page 65). <http://cdmrp.army.mil/aboutus>
- 2016 Chaired, Technical Challenges in Particle Toxicology session on September 26 at 11<sup>th</sup> International Particle Toxicology Conference in Singapore
- 2017 Co-organized NIEHS workshop, Asbestos health effects on July 31, 2017 at Davis Center, UVM. Gave a talk in biomarker session and participated in the panel discussion. Moderated asbestos cancer outcome session.
- 2018 Findings of our paper in the FASEB J (March 2018) were highlighted in:
  - Press release [https://www.eurekalert.org/pub\\_releases/2018-03/foas-fjn031218.php](https://www.eurekalert.org/pub_releases/2018-03/foas-fjn031218.php)
  - ATI news report <http://allthatsinteresting.com/asbestos-detection>
  - College of medicine [http://www.med.uvm.edu/com/news/2018/03/27/shukla\\_research\\_highlights\\_how\\_asbestos\\_causes\\_lung\\_disease\\_mesothelioma](http://www.med.uvm.edu/com/news/2018/03/27/shukla_research_highlights_how_asbestos_causes_lung_disease_mesothelioma)
  - NIEHS papers of the month
  - Asbestos.com
  - NIEHS papers of the year 2018
 We were selected as one of 25 (out of 2,900) studies to be highlighted as paper of the year by NIEHS!  
<https://factor.niehs.nih.gov/2019/1/feature/2-feature-papers-of-the-year/index.htm>
- 2018-2019 External Advisory Committee, Penn SRP Center and Training Program, Perelman School of Medicine, University of Pennsylvania.
- 2018 Our research funded by the U.S. Department of Defense Peer Reviewed Cancer Research Program (PRCRP) was highlighted on the Congressionally Directed Medical Research Programs (CDMRP) website  
[http://cdmrp.army.mil/prcrp/research\\_highlights/18shukla\\_highlight](http://cdmrp.army.mil/prcrp/research_highlights/18shukla_highlight)  
<https://go.usa.gov/xUzwz>
- 2018 My research/lab profiled on Asbestos.com under research centers  
<https://www.asbestos.com/treatment/research-centers/shukla-lab-uvm/>
- 2019 Better Together Award for team work on IPF (UVMCC)
- 2019 Quoted in VTDigger article on social services group's asbestos violation, "NEK social services group paid fines for asbestos, other violations", regarding the link between asbestos and lung disease.
- 2019 Michael Hasson Lectureship award for mesothelioma, OSHU, Portland, Oregon.

- 2020 Served on Toxic Substances Control Act (TSCA) Science Advisory Committee on Chemicals (SACC) meeting to peer review EPA's draft risk evaluation of Asbestos.
- 2021 Society of American Asian Scientists in Cancer Research (SAASCR), Outstanding Achievement Award for seminal contributions to the field of cancer research, 2021. Presented in AACR Annual Meeting May 17, 2021, virtual meeting.
- [https://www.indiawest.com/news/global\\_indian/eight-indian-american-scientists-honored-by-saascr-for-cancer-research/article\\_0f0cd756-c374-11eb-ae9d-e34b69801398.html](https://www.indiawest.com/news/global_indian/eight-indian-american-scientists-honored-by-saascr-for-cancer-research/article_0f0cd756-c374-11eb-ae9d-e34b69801398.html)
- <https://www.indiapost.com/indian-american-scientists-awarded-for-cancer-research-discoveries-by-saascr/>
- 2022 Shukla Research was featured on Asbestos.Com  
<https://www.asbestos.com/blog/2022/08/15/shukla-lab-asbestos-therapy/>

### **KEYWORDS/AREA OF INTERESTS**

Environmental lung diseases, environmental cancers, asbestos, carbon nanotubes, lung cancer, mesothelioma, exosomes, biomarkers, inflammasomes, inflammation, microbiome, lung fibrosis, pleural fibrosis, mesothelial cells, signaling molecules (ERKs, CREB, PKCs), massively parallel sequencing, proteomics, miRNAs, nano-particles, cancer therapy, mesothelial to fibroblastic transition, xenograft and allograft mouse models for mesothelioma.

### **SUMMARY OF ACCOMPLISHMENTS**

- Obtained multiple extramural grants (MARF, NIH RO1&R21, DoD) as PI and numerous (9) internal grants to support my research. Established and successfully running independent research program on mesothelioma.
- Published research papers, reviews, editorial, commentary, encyclopedia chapter and book chapters in high impact factor peer reviewed journals. My complete list of publication has 105 articles and Google scholar citation is 7685 (h-index 45).
- Highly recognized nationally and internationally in the field as depicted by speaker invitations (eg. Gordon Conference and Mike Hasson lecture from Portland Oregon), External Advisory Committee (Penn, SRPCTP) as well as grant reviewer/chair invitations from NIH, Department of Defense (DoD) and various European agencies. Won numerous awards. My research was profiled on Asbestos.com in 2018 and 2022.
- Trained undergraduates, master and PhD students and post-doctoral associates.
- Successfully directed Pathology Master Program for 2 years.
- Inducted into COM Teaching Academy as a charter member due to my dedication to education and mentoring.
- Co-organized NIEHS workshop.
- Served on Toxic Substances Control Act (TSCA) Science Advisory Committee on Chemicals (SACC) meeting to peer review EPA's draft risk evaluation of Asbestos.

[PDF] [TSCA Scientific Advisory Committee on Chemicals](#)

## PROFESSIONAL SERVICE

### DEPARTMENTAL SERVICE

<b>Years</b>	<b>Department</b>	<b>Committee</b>	<b>Role</b>
2021-2024	Pathology and laboratory Medicine	Pathology RPT	Member
2017-Present	Pathology and laboratory Medicine	Pathology Communications committee	Member
2016-2019	Pathology and laboratory Medicine	Pathology Grand Round planning committee	Member
2014-2015	Pathology and laboratory Medicine	Reappointment, Promotion and Tenure (RPT) committee	Member
2014-Present	Pathology and laboratory Medicine	Advancing Knowledge Council	Member
2013-Present	Pathology and laboratory Medicine	Redox Biology and Pathology (RBP) group	Member
2013-2015	Pathology and laboratory Medicine	Pathology Master Program	<b>Director.</b> In addition to running the program, my responsibilities also involved overseeing the progress/problem of each student enrolled (total 4 under my directorship). I met with them occasionally or as per their requirements to get an update of their progress. If required, I contacted their advisors to get an update.
2010-2013	Pathology and laboratory Medicine	Environmental Pathology Training Grant Program	I was mentor/faculty in the program. I taught and mentored students. I was also steering committee member of the program and coordinator for the environmental pathology and carcinogenesis seminar series

2012	Pathology and laboratory Medicine	Evaluation of Chair candidates	Involved in the process of evaluation of Chair candidates for the department
2010-2013	Pathology and laboratory Medicine	Evaluation of Postdoctoral candidates for the Environmental Pathology Training program	I regularly interviewed and evaluated postdoctoral candidates for the Environmental Pathology Training program

**COLLEGE SERVICES**

<b>Years</b>	<b>College</b>	<b>Committee</b>	<b>Role</b>
2022	LCOM	Excellence in Research celebration for the Larner College of Medicine	Reviewer
2022, May	MMG, Faculty candidate interview		Interview and evaluation
2021-	University of Vermont Larner College of Medicine	Mentoring committee, Teaching Academy	Member
2021-	University of Vermont Larner College of Medicine	Writer's workshop Teaching Academy	Reviewer
2015-2018	University of Vermont Larner College of Medicine	CMB (Cellular, Molecular and Biological Sciences) Faculty Membership Committee	<b>Chair</b> As a chair of the CMB Faculty Membership Committee I organized the review process for membership application from new members seeking to attain CMB membership and application renewal from existing members (every 3 years)
2015-2018	University of Vermont Larner College of Medicine	CMB Steering committee	Member
2014-Present	University of Vermont Larner College of Medicine (UVMCC)	American Cancer Society (ACS)- Institutional Grant review committee	Member Grant reviewer for applications for submission to ACS and mentor junior faculty

2012-2015	University of Vermont Lerner College of Medicine	COM Faculty Standards Committee	Member, evaluated applications for reappointments, promotion and tenure. Committee met in winter and spring. Depending upon the number of applications it took 4-5 meetings of 2 hour each for both seasons to complete the process.
2012-2018	University of Vermont Lerner College of Medicine	CMB Faculty Membership Committee	Member, evaluated applications from new CMB membership candidates as well as renewal applications from existing members
2012-Present	University of Vermont Lerner College of Medicine	Cellular, Molecular and Biomedical (CMB) faculty	Faculty of CMB mentoring students of this program. In addition, I attend CMB seminars and evaluate them on a regular basis. I am also actively involved in the recruitment interviews and qualifying exams of the students. Reviewed papers for Alpert award (2016)
2013	University of Vermont Lerner College of Medicine (UVMCC)	Interview/Evaluation of Faculty candidates	Evaluated/interviewed two candidates for VCC Translational lab
2013	University of Vermont Lerner College of Medicine	Interview/Evaluation of Faculty candidates	Interviewed/evaluated a faculty candidate for Hematology-Oncology division

### UNIVERSITY SERVICES

<b>Years</b>	<b>University</b>	<b>Committee</b>	<b>Role</b>
2014-Present	University of Vermont	Indian Student Association (ISA), UVM	Faculty Advisor for Indian Student Association (ISA), UVM.
2012-2015	University of Vermont	Undergraduate Research Advisory committee	I evaluated grant applications (Fall, Spring and Summer) from undergraduate students sponsored by the Honor College, UVM
2012	University of Vermont	Dean's (The Extension) evaluation committee	This review/reappointment process involved extensive work for three months. The process included committee meetings, open houses and interview with interested

individuals and compilation of reports.

2006- Present	University of Vermont	University of Vermont Cancer Center (UVMCC)	Full member: Attend meetings, present my work at meetings or journal clubs, write grants, participate in outreach program, take part in interviewing faculty candidates and translational lab candidates. Review grant applications for UVMCC and ACS.
------------------	--------------------------	---	--

SERVICES AT NATIONAL & INTERNATIONAL LEVELS

<b>Years</b>	<b>Organization</b>	<b>Committee</b>	<b>Role</b>
2018- 2019	Perelman School of Medicine, UPenn.	External Advisory Board	member for Penn Superfund Research Program Center and Training Program
2017	<b>NIH</b>	NIEHS Asbestos health effect workshop	Co-organizer
2009	<b>NIH</b>	Grant review	Phase 1 Reviewer for <b>RC1-NIH</b> grants (ZRG1 OTC-K). Reviewed 3 grants.
2009	<b>Louisiana Board of Regents</b>	Grant review	Reviewed Pilot funding grant
2010	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited pre-proposal reviewer of Investigator Initiated Research Awards (IIRA)
2010	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited Reviewer for Concept awards
2010	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited Reviewer for grants in IIRA and Technology/Therapeutic development (TTD) categories, Mesothelioma Panel, September 29-October 1
2012	<b>Health Research Board, Dublin, Ireland</b>	Clinical and Applied Biomedical Research	Invited reviewer for Clinical and Applied Biomedical Research grants
2012	<b>British Lung Foundation, UK</b>	Burrow Hill Research Grant	Invited reviewer for Burrow Hill Research Grant applications



2012	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited Reviewer of IIRA Pre-Proposals in the area of Nanomedicine for Drug Delivery Science
2012	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited Reviewer of grant applications in the area of Nanomedicine for Drug Delivery Science
2012	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited Reviewer, PRMRP, DoD Investigator Initiated research Award/Technology Therapeutic Development Award mechanism for Nanomedicine for Drug Delivery Sciences topic area via Teleconferencing session September 17-18. (I declined to participate due to conflict with hosting UVM/COM, Environmental Pathology and Carcinogenesis seminar series speaker that day)
2012	UVM/COM	VCC/LCCRO	Ad hoc reviewer of VCC/LCCRO grant application
2012	<b>European Science Foundation (ESF)</b>	Junior PI grant review mechanisms	Invited reviewer of grants under Junior PI grant review mechanism
2012	<b>US Department of Defense (DOD)</b>	Kidney cancer and mesothelioma panel	Invited to serve as a scientist reviewer (panel member) for kidney cancer and mesothelioma panel (CDMRP, DoD) Nov 2012. (Declined due to time conflict)
2012	<b>NIH</b>	Early Career Reviewer (ECR) program at the Center for Scientific Review (CSR)	Accepted for participation in the Early Career Reviewer (ECR) program at the Center for Scientific Review (CSR), NIH
2013	<b>Health Effects Institute (HEI), Boston, MA</b>	Final Report	Final Report reviewer
2013	<b>NIH</b>	NCI peer review panel	Invited to participate in NCI peer review panel, March 28-29
2013	<b>Medical Research Council, UK</b>	Grant review	Invited reviewer for Medical Research Council, UK grant

2013	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited reviewer for grants submitted in the area of Discovery Award-Technology
2014	<b>National Science Center, Poland</b>	Grant review	Invited reviewer for National Science Center, Poland
2014	<b>US Department of Defense (DOD)</b>	Lung Cancer Research Program (LCRP)	Peer review panel of the 2014 Lung Cancer Research Program (LCRP), Nov 12-14, 2014.
2015	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited reviewer for the Pre-application Acute Lung Injury-2 (PRE-ALI-2) peer review panel of the 2015, June-July, 2015
2015	<b>US Department of Defense (DOD)</b>	Congressionally Directed Medical Research Programs (CDMRP) and Peer Reviewed Cancer Research Program (PRCRP), Idea Award with Special Focus Award (IdeaA-SF) and the Career Development Award (CDA)	Invited on site reviewer for Cellular and Molecular Biology (CMB) peer review panel of the 2015 Lung Cancer Research Program (LCRP), Nov 8-10, 2015.
2016	<b>NIH</b>	K08/K23 Grant mechanism of NIEHS	Invited reviewer for National Institute of Environmental Health Science K08/K23 Grant Applications. March 2016
2016	Kom op tegen Kanker ( <b>stand up to cancer</b> ) <b>Koningsstraat 217 - 1210 Brussel</b>	Biomedical Commission	Invited reviewer for the Biomedical Commission of <b>Kom op tegen Kanker (stand up to cancer)</b>
2016	<b>CDC/NIOSH</b>	National Mesothelioma Virtual Bank (NMVB)	Invited reviewer for <b>CDC/NIOSH</b> , National Mesothelioma Virtual Bank (NMVB) renewal application. May 2016
2016	<b>UVM/COM</b>	VCC/LCCRO	Invited reviewer for UVMCC/ LCCRO grant applications, May 2016

2016	<b>US Department of Defense (DOD)</b>	Lung Cancer Research Program (LCRP)	Invited reviewer, Cell Biology (CON-CB) peer review panel of the 2016 Lung Cancer Research Program (LCRP), September-October 2016
2016	<b>US Department of Defense (DOD)</b>	Peer Review Cancer Research Program (PRCRP)	Member, Mesothelioma (MESO) peer review panel, October-November 2016
2016	<b>UVM/COM</b>	VCC/LCCRO	Invited reviewer for UVMCC/LCCRO application, October-November 2016
2017	<b>UVM/COM</b>	VCC/LCCRO	Invited reviewer for UVMCC/LCCRO application, March 2017.
2017	<b>MRC Toxicology Unit, University of Leicester, UK</b>	Review of scientific programmes (Past and Future Plans)	Invited to review scientific programme (Past and future plans) of the MRC Toxicology Unit, University of Leicester, UK
2017	<b>US Department of Defense (DOD)</b>	Lung Cancer Research Program (LCRP)	Invited reviewer Cell Biology (CON-CB) peer review panel, September-October 2017
2017	<b>US Department of Defense (DOD)</b>	Lung Cancer Research Program (LCRP)	Invited to <b>Chair</b> Meso-panel, PRCRP, Department of Defense, November 2017. (Declined due to unavailability)
2018	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited reviewer Pre-Metals Toxicology (pre-MT) peer review panel, June-July 2018
2018	<b>Wellcome Trust/ DBT India Alliance</b>	Fellowship mechanism	Invited to review the Welcome Trust/DBT India Alliance fellowship application.
2018	<b>US Department of Defense (DOD)</b>	Lung Cancer Research Program (LCRP)	Invited reviewer and <b>ad hoc chair</b> for Cell Biology (CB) peer review panel of the 2018 Lung Cancer Research Program (LCRP), October 2018
2019	<b>UVM</b>	Vermont Genetics Network (VGN) grant	Invited reviewer for Vermont Genetics Network (VGN), UVM.
2019	<b>US Department of Defense (DOD)</b>	Peer Reviewed Medical Research Program (PRMRP)	Invited reviewer for Pre-Metal Toxicology pre-(MT) peer review panel of the 2019 Peer Review Medical Research Program (PRMRP), April, 2019

2019	<b>NIH</b>	NIEHS Superfund Review	Invited reviewer for P42 Superfund Review Meeting, NIEHS, NIH. June-July 2019
2019	<b>US Department of Defense (DOD)</b>	Lung Cancer Concept Awards (CDRMP)	Invited reviewer, September-October 2019
2019	<b>US Department of Defense (DOD)</b>	Lung Cancer(IITR)	Invited reviewer, lung cancer panel October 2019
2020	<b>NIH/NIMHD</b>	Specialized Centers of Excellence on Environmental Health Disparities Research P50	Invited review panel member, March 10-12
2020	<b>US-Israel Binational Science Foundation</b>	Annual BSF competition for research grants	Invited reviewer
2020	<b>Vermont Genetics Network</b>	Research grant	Invited reviewer
2020	<b>Environmental Protection Agency(EPA)</b>	Toxic Substance Control Act, Science Advisory Committee on Chemicals (SACC)	Invited reviewer for EPA's draft risk evaluation of Asbestos.
2020	<b>US Department of Defense (DoD)</b>	Lung Cancer Concept Awards (CDRMP)	Invited reviewer, July, 2020
2020	<b>US Department of Defense (DoD)</b>	Lung Cancer Research Program	<b>Chair</b> , September 2020
2020	<b>US Department of Defense (DoD)</b>	Peer Reviewed Cancer Research Program-Meso	Invited reviewer Nov 2020
2021	<b>NIH/NIEHS</b>	R01 US-India Collaborative Environmental Health Research Program (all BCC)	Invited reviewer March 10/11, 2021
2021	<b>British Lung Foundation</b>	Peer review of research grant proposal	Invited reviewer April 23, 2021
2021	<b>NIH/NIEHS</b>	Superfund P42 grants	Invited reviewer Phasel&II, September/October 2021
2021	<b>US Department of Defense (DoD)</b>	Rare cancer, Meso panel	<b>Chair</b> , September/October 2021

2022	<b>NIH/NIEHS</b>	Elucidating Tissue/Cell specific Pathophysiological Mechanisms: Chemical-Induced Effects and Biological Response. Lung Cancer Research Program	Invited reviewer March 2022
2022	<b>US Department of Defense (DoD)</b>	R21&R03	Invited reviewer June, 2022
2022	<b>NCI/NIH</b>	Lung cancer	July 2022
2022	<b>DoD</b>		<b>Chair</b> , Sep 2022
2023	<b>NIH</b>	EDD study section	Reviewer, Nov 2023
2023	<b>DoD</b>	Rare Diseases	Reviewer, Oct 2023
2023	<b>DoD</b>	RCRP MESO	Reviewer, Dec 2023
2023	<b>DoD</b>	CDMRP	Chair, Nov 2023
2024	<b>NIH</b>	NIH Counteract Program	February, 2024
2024	<b>NIH</b>	Superfund Research program	June, 2024

#### SERVICE TO PROFESSIONAL ORGANIZATIONS

<b>Years</b>	<b>Society</b>
2006-2018	<b>Society for Free Radical Biology and Medicine (SFRBM)</b> : Active member, Review papers for the society journal (FRBM). Serve as a volunteer judge (FY2010, 2011, 2012, 2013, 2014, 2015) to evaluate abstracts for oral presentation for Society of Free Radical Biology and Medicine.
2006-2020	<b>American Association for Cancer Research (AACR)</b> : Active member, Attend and present my work to the annual society meeting. Sponsor abstracts and/or membership applications for new members or non-members

2014-2016 Reviewed abstracts for 2014 **International Mesothelioma Interest Group (iMig)** meeting in South Africa.

Invited member of scientific abstract review committee **iMig**. Reviewed abstract for 2016 in UK.

SERVICE TO PROFESSIONAL PUBLICATIONS

<b>Years</b>	<b>Journal/Publication/Editorial board member</b>
2010-2016	American Journal of Respiratory Cell and Molecular Biology (ATS Journal): Editorial board member, Reviewed for the journal
2014-present	Air and Water Born Diseases (OMICs group): Editorial board member, write editorial or research paper for the journal.
2012-present	American Medical Journal (Science Publication): Editorial board member, write for the journal and review submitted articles, handle articles by assigning to different reviewers and provide final recommendations for the publication
2012-present	Journal of Cancer Research and Therapy: Editorial board member, handle manuscripts for the journal. Assign reviewers, collect their comment to create an editorial report and provide my decision to the journal staff to communicate with authors.

**Reviewed papers for over 40 different journals (listed below).**

American J Pathology; American Journal of Physiology - Lung Cellular and Molecular Physiology; American Journal of Respiratory Cell and Molecular Biology; American Medical Journal; Biologicals; BMC-Cancer; BMC-Genomics; British J Cancer; Cancer Cell International; Cancer Letters; Cancer Research (AACR), Carcinogenesis, Cell Biology and Toxicology; Cellular and Molecular Biology Letters; Clinical Cancer Research (AACR); Environmental Pollution; Free Radical Biology and Medicine; Inhalation Toxicology; International Journal of Cancer; International Journal of Nanomedicine; In Vitro Cellular and Developmental Biology-Animal; Journal of Cellular Biochemistry; Journal of Ovarian Research; Journal of Toxicology and Environmental Health; JCI Insight; Life Sciences; Lung; Lung Cancer; Molecular Cancer, Molecular Cancer Therapeutics (AACR); Nutrition Reviews; Nature Communications; OncoTargets and Therapy; Oncotargets; Particle & Fibre Toxicology; PLoS one; Respiratory Physiology and Neurobiology; Respiratory Research; The Annals of Respiratory Medicine; The International Journal of Biochemistry & Cell Biology; Toxicology Letters, Translational Research

PUBLIC SERVICE

<b>Years</b>	<b>Service Role</b>
2013-2014	I gave lab tour to Colchester high school student as a part of VCC community Outreach Program, April 1, 2013, tour to Johnson State High

School students, June 25, 2013, and tour to Harwood high school, May 2, 2014. The purpose was to teach community about environmental cancers.

- 2013 Microarray data generated by my group were used to educate people at Johnson State College, Department of Environmental and Health Sciences Community Seminar Series (4:00-5:15 206 Bentley Hall). Presented by Mr. Timothy Hunter **2013**.
- 2018 Participated in UVM Summer Academy program, Panel: Basic Science and Genomic Discussion. Discussed my research with high school students. July 11, 2018 10:30-12.

### SUMMARY OF SERVICE ACTIVITIES

Served on many committees of University, College and Department (including COM Faculty Standards Committee) in last many years and still serving on some (AKC-Departmental; ACS review committee-UVMCC etc.). At national and international level, I serve (d) as editorial board member for 4 journals, reviewed papers for over 40 different journals, reviewed grants for NIH, DoD and various European agencies. For many years I served as member of AACR and FRBM societies and helped with sponsoring and judging abstracts for the meetings.

### TEACHING

Year	Course Title	R	E	Hours	Number of Learners	Learner Level
2006	Path 305 Molecular Mechanisms of Environmental Diseases		x	4		Graduate/post graduate
2008	Path 305 Molecular Mechanisms of Environmental Diseases		x	4	8	Graduate/post graduate
2010	Path 305 Molecular Mechanisms of Environmental Diseases		x	4	13	Graduate/post graduate
2011	Path 395 Readings in Environmental Pathology		x	4	3	Graduate/post graduate
2012	Path 305 Molecular Mechanisms of Environmental Diseases		x	4	12	Graduate/post graduate
2016	CLBI 295 Cellular and Molecular Pulmonology		x	6	7	Graduate/post graduate
2021	Path 307 Molecular Pathology			1.5	2	Graduate
2022	Path/GNRS325 Genetics for Clinicians			16 weeks	30	Post graduate (nursing & MLS)
2022	Path 307 Molecular Pathology			1.5	2	Graduate

2023	Path/GNRS325 Genetics for Clinicians			16 weeks	30	Post graduate (nursing & MLS)
2023	Path 307 Molecular Pathology (mesothelioma)			1.5	5	Graduate
2023	Path 307 Molecular Pathology (Organoids)			1.5	5	Graduate
2024	Path 6090 (Director)					Graduate
2024	Path/GNRS6250 (Director) Genetics for Clinicians			16 weeks	30	Post graduate (nursing & MLS)
2024	Path 307 Molecular Pathology (mesothelioma)					
2024	Path 307 Molecular Pathology (Organoids)					

2015-2025                    **Member-UVMCOM Teaching Academy**

Jan 2024-present        Director, Path MS (Thesis track)

Mentoring:

A big chunk of my time is devoted to mentoring students. The mentoring ranges from helping them gain laboratory experience, discussing ideas and troubleshooting to getting MS or PhD degrees. The students I mentored in the last many years and those mentoring presently are listed below:

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

<b>Dates</b>	<b>Name</b>	<b>Program School</b>	<b>Role</b>	<b>Current Position</b>
2007-2012	Sherrill A. Lathrop, PhD student at UVM	Environmental Pathology/CMB	Co-mentor	Working at FDA
2008-2013	Kheng Newick, PhD student	Cellular Molecular & Biological Sciences	Co-mentor	Scientific writer
2009-2012	Timothy N. Perkins,	Pathology Master Program	Co-mentor	Faculty
2009-2012	Mutlay Sayan,	Pre-med student at UVM	Co-mentor	Residency program
2010-2016 2012- 2016 2012- 2012	Joyce Thompson Graduate/PhD student Rotation student Exchange student from Ghana	Cellular Molecular & Biomedical Sciences	Mentor	Post-doctoral associate at the University of Michigan Cancer Center, Ann Arbor, MI



2010-2011	Elizabeth Claire Yasewicz,	Undergraduate pre-med student, UVM	Faculty Apprentice Advisor	
2012-2014	Catherine Westbom,	Pathology Master Program	Mentor	Residency program
2012-2014	Sonali Herath, MS student	Pathology Master Program	Co-mentor	Physician's Assistant program at Duke University.
2011-2016	Alden Clemments	Graduate student Chemistry Department, UVM	Co-mentor	
2013-2014	Anurag Shukla	Medical student at UVM	Mentor	Anesthesiologist with US Anesthesia Associates, Denver, CO
2015-2019	Phillip Munson,	Graduate student Cellular Molecular & Biological Sciences	Mentor	Scientific Affairs Manager, miRNA cancer diagnostics.

#### DISSERTATION/THESIS COMMITTEE MEMBERSHIP

2014-2020	<b>Michelle DiPinto, PhD candidate</b> , Chemistry Department, Advisor, Dr. Christopher Landry.
2014-2017	<b>Peibin WO, MS candidate, CMB</b> , Advisor Dr. Karen Lounsbury. <b>Chair of the committee.</b>
2012-2014	<b>Sonali Herath, MS candidate</b> , Pathology Department. Advisor-Dr. Brooke Mossman.
2009-2016	<b>Alden Clemments, PhD student</b> , Chemistry Department, Advisor-Dr. Christopher Landry.
2009-2012	<b>Timothy Perkins, Master student</b> , Department of Pathology, UVM, Advisor, Dr Brooke Mossman.
2007-2012	<b>Sherrill Lathrop, PhD student</b> , Department of Pathology, UVM. Advisor, Dr. Brooke Mossman.
2008-2009	<b>Maggie Sager, Undergraduate Research</b> (Honor College Thesis), College of Medicine, UVM. Advisor, Joseph D. Schmoker. <b>Chair of the committee.</b>

2008

**Ms Pandima Devi, Ph.D. (Thesis examiner)** A PhD thesis from the University of Madras, Guindy Campus, Chennai, TN, India. Advisor, Dr. V. Kannan.

POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED

<b>Dates</b>	<b>Name</b>	<b>Program School</b>	<b>Role</b>	<b>Current Position</b>
2007-2010	Jedd M. Hillegass, PhD	Pathology & Laboratory Medicine Department	Co-mentor	Toxicologist at BMS New Brunswick, NJ .
2007-2011	Jeremy L. Steinbacher, PhD	Chemistry Department	Co-mentor	Assistant Professor at the University of Buffalo, NY
2011-2013 & Nov 2016	Jill M. Miller, MD	FAHC & Pathology & Laboratory Medicine Department	Mentor	Attending Physician at Montana hospital
2012-2013	Sameer Kaiser, MD, a research resident	Surgery Department	Co-mentor	

OTHER VISITING FACULTY SUPERVISED

<b>Years</b>	<b>Names</b>	<b>University/College</b>
2011-2013	Julia Zhao, MD	Professor, Guangxi Medical University, China

OTHER STUDENTS MENTORED

<b>Dates</b>	<b>Name</b>	<b>Program School</b>	<b>Role</b>	<b>Current Position</b>
2007-2007	Sarah Flickinger	High school graduate	Mentor	
2007-2007	Sarah Sullivan	Undergraduate at UVM	Mentor	
2008-2008	Priyam Vijai Patel	Undergraduate at UVM	Mentor	
2010-2013	Christopher Cason	Undergraduate at UVM	Mentor	Dental surgeon, Texas.
2013-2015	Alan Leonard Leggett	Undergraduate student at UVM	Mentor	PhD student at the Brown University

2014-2014	Helen Kogan	A high school senior from NY	Mentor	Presently in Columbia University, graduate program.
2015-2016	Sara Friedman	undergraduate student at UVM	Mentor	Graduated from UVM medical school
2015-2016	Santhoshini Premsankar	Middle school Essex, VT	Mentor	High school
2016-2019	Niveditha Badrinarayanan	undergraduate student at Honors College, UVM	Mentor	3 <sup>rd</sup> year UVM med school
2016-2017	Emma Walde,	Post-bac student at UVM pre-med program	Mentor	
2017-2017	Anushree Bajpai	B. Tech student from VIT, India under their Semester Abroad Program	Mentor	Associate Scientist at Takeda, Boston, MA
2018-2018	Elizabeth Hall	Undergraduate at UV	Mentor	Undergraduate at UV
2018-2018	Rachelle Schwanen	BS student from Netherland under semester abroad program	Mentor	Netherland
2019-2020	Brennan Huff	undergraduate student at UVM	Mentor	graduated
2020 (July-August)	Ellie Hall	Summer student	Mentor	
2022	Maggie King	MS Pathology, rotation student	Advisor	

**Summary of Teaching Activities**

Taught small classes of graduate students and postdocs in Environmental Pathology Program (2006-2012), 2016 in CMB and Path Master program (2021, 2022, 2023). Co-instructor of Genetics for Clinician course (Spring 2022, 2023). Mentored numerous high school students, undergraduates, graduate and post-doctoral associates. Successfully directed Pathology Masters program for 2 years. Two master students, 2 PhD students, one postdoctoral associate and number of undergraduate students graduated/trained from my lab. My excellent teaching and mentoring record led to my induction in LCOM Teaching Academy in 2015.

## **RESEARCH AND SCHOLARLY ACTIVITIES**

### **Research support (Grants)**

#### **Current**

Pathology Department grant (Shukla PI). January 1, 2022-December 31, 2022  
To assess gene expression profile in PFOA exposed mice lungs

#### **Completed**

1 R21 ES028857- Shukla (PI) 07/01/18-06/30/2020  
01A1 NIH/NIEHS (06/30/2021, NCE)  
*Unfolded Protein Responses in Carbon Nanotube-Induced Mesothelial Cell Fibrosis and Mesothelioma.*

The goal of this study is to evaluate the role of unfolded protein response (UPR) in multi-walled CNT (MWCNT) or single-walled CNT (SWCNT)-induced mesothelial cell fibrosis and MM development. Successful completion of this project will reveal novel mechanisms associated with fiber-induced mesothelial cell pathogenesis, and will further inform the hazards associated with MWCNT exposure in advancing the discovery of new therapies.

Role: PI  
Direct Costs Year 1: \$125,000  
Total Period: 2 years

**LCOM Bridge funding** Shukla (PI) 04/2017-05/2019  
*Role of CD4+T cells in asbestos-induced mesothelial to fibroblastic transition (MFT)*

The goal of this study was to understand how activation of inflammasomes in CD4+T cells generate Th2 response and regulate mesothelial cells fibrosis initiation in response to asbestos.

Role: PI  
Direct Costs Year 1: \$50,000  
Total Period: 2 years

R35 HL135828

Janssen-Heininger (PI)

1/01/2017 – 12/31/2023

**NIH/NHLBI**

*S-glutathionylation chemistry in fibrotic lung remodeling*

The goal of this study is to understand the importance of the process of S-glutathionylation in patients with asthma or pulmonary fibrosis, and in mouse models of these diseases. The goal is to understand how this process of S-glutathionylation works, and whether the enzymes that regulate this process can be a target for more specific drugs. We believe that these questions are important for translation into clinical practice as we already have data with compounds that can be used clinically.

Role: Co-I  
Direct Costs Year 1: \$600,000  
Total Period: 7 years

**Paredox**

Heintz (PI)

07/01/2017-06/30/2019

**Therapeutics LLC**

*Exploiting Mitochondrial Oxidants as a Therapeutic Target in Malignant Mesothelioma*

The goal of this study is to explore mechanisms for inactivating the peroxiredoxin 3 antioxidant network in tumor cell mitochondria as a therapeutic approach for treating malignant mesothelioma.

Role: Co-I  
Direct Costs Year 1: \$484,040  
Total Period: 3 years

**UVM REACH**

Shukla (PI)

5/2017-10/2018

*Exosomal micro RNA for early diagnosis of mesothelioma*

The goal of this study was to profile the exosomal miRNAs from mesothelioma tumor cells.

Role: PI  
Total cost: \$30,000  
Total Period: 18 Months

01/2012-9/2016

**R01 ES021110**

Shukla (PI)

April 2018-NCE

**NIH/NIEHS**

*Inflammasomes in Pathogenesis of Mesothelioma*

The goal of this study was to understand the role(s) of inflammasome in development of mesothelioma and to exploit the inflammasomes as therapeutic target for mesothelioma treatment.

Role: PI  
Direct cost year 1: \$225,000  
Total Period: 5 years+18 months NCE

09/2014-08/2017

Total cost \$25,000  
Total Period 12 months

**UVMCC/LCCRO**

07/2016-06/2017

The goal of this study was to understand if asbestos instillation in lungs disturbs the lung and gut microbiome resulting in systemic inflammation related changes and pathogenesis (fibrosis) of lung.

Role: PI  
Total cost \$65,000  
Total Period 1 year  
**W81XWH-13-PRCRP-** Shukla (PI)

**IA, Department of Defense (DoD)**

*Exosomes in development and therapy of mesothelioma*

The goal of this study was to understand how exosomes can transmit signals from lung cells to mesothelium to cause mesothelioma development. Another goal was to identify exosomal biomarkers of asbestos exposure and/or mesothelioma for early diagnosis of this cancer.

Role: PI  
Direct cost year 1 \$150,000

**R13 NIEHS workshop** on novel research findings on asbestos health effects. 7/31/2017

MPI

Total Period 2 years+12 months NCE

**Department of Surgery Research Grant, UVM** James (PI)

9/1/15-11/1/16

The goal of this study was to design decorated silica microparticles to target melanoma cells for drug delivery.

**Lake Champlain Cancer Research Organization Bioinformatics funding** Shukla (PI)10/2015-12/2015

*Splice variant identification in asbestos exposed mesothelial cells*

The goal of this study is to identify splice variants in response to asbestos exposure to mesothelial cells.

Role: PI

**Lake Champlain Cancer Research Organization** Shukla (PI)

09/01/2013 - 08/31/2014

*Preclinical evaluation of ERK5 inhibitors for malignant mesothelioma growth suppression*

The goal of this project is to assess effects of specific ERK5 inhibitor, XMD8-92 on in vitro and in vivo MM tumor growth.

Role: PI  
Total cost \$50,000  
Total Period 1 year

**Vermont Cancer Center/Lake Champlain Cancer Research Organization (VCC/LCCRO)** Shukla (PI) 01/01/12 - 12/31/12

*Massive Parallel Sequencing in Human Primary Mesothelial Cells in Response to Crocidolite Asbestos Exposure*

The goal of this project is to identify differential susceptibility of pleural and peritoneal mesothelial cells to asbestos

Role: PI  
Total cost \$20,000  
Total Period 1 year

**Mesothelioma Applied Research Foundation (MARF)** Shukla (PI) 1/1/10-6/30/12

*Bifunctionalized APMS Particles to Target ERK5 in Malignant Mesothelioma Treatment*

The Major goal of this project was to develop combination therapy for mesothelioma utilizing APMS particles loaded with ERK5 inhibitor and chemotherapeutic drugs.

Role: PI  
Total cost \$100,000  
Total Period 2 years+1 year NCE

**Vermont Cancer Center/Lake Champlain Cancer Research Organization** Shukla (PI) 09/01/08-08/31/09

*Role of MAPK Phosphatases in Malignant Mesothelioma*

The major goal of this project is to identify MAPK phosphatases (negative regulator of MAPK signaling) as target for MM treatment using in vitro models

Role: PI  
Total cost \$50,000  
Total Period 1 year

08/15/2008-05/31/2009

**INBRE-NIH** Shukla (PI)  
**P20RR016462-**  
**086071-VGN**  
*CREB-Target Genes in Malignant Mesothelioma*

The major goal of this project is to identify CREB-regulated genes in human MM cells as compared to mesothelial cells.

Role: PI  
Total cost \$5000  
Total Period 1 year

**P01 HL046703** Mann PD; Bovill (PL) Project 6 09/01/2007-07/31/2012  
**NIH/NHLBI**  
*Surface Dependent Reactions in Thrombosis and Thrombolysis (Project 6: Genomic Approach to Gene-Gene Interaction in Thrombophilia)*

We have identified Cell Adhesion Molecule-1 (CADM1) as a novel venous thrombosis risk gene that interacts with protein C deficiency in large French-Canadian kindred. The laboratory is presently focused on investigating the phenotypic role of this gene in thrombogenesis. CADM1 appears to play a synergistic role with activated protein C in modulating endothelial barrier function.

Role: Co-I  
Total Period 5 years

**P01 CA11407** Carbone PD; Mossman (PL) 09/01/2006-08/31/2011  
**NIH/NCI**  
*Pathogenesis of Mesothelioma (Project 2: ERK Pathways in Pathogenesis and Chemoresistance of Mesothelioma)*

This inter-institutional (Cancer Research Center of Hawaii, UVM, Fox Chase Cancer Center, New York University and University of Chicago) P01 grant consists of experimental and epidemiologic studies on mechanisms of SV40 and asbestos-associated mesothelioma. Dr. Mossman's project will explore the possibly divergent effects of ERKs1/2 and ERK5 in SV40-asbestos cocarcinogenesis and tumor growth using human mesothelioma cells and a nude mouse xenograft model.

Role: Co-I  
Total Period 5 years



**1PO1 HL6767004-01** Mossman (PD and PL)  
**NIH/NCI**

6/1/2001-4/30/2007

*Signaling in Epithelial Injury, Proliferation and fibrosis. Project 3: "Protein kinase C and MAPK in epithelial Responses*

The major goal of this project was to study role of PKCs in asbestos-induced fibrosis.

Role: Co-I  
Total Period 5 years

**Not funded**

**R21 Shukla (PI)**  
**NIH/NHLBI**

7/1/2020-6/30/2022

GLUTATHIONE, ER REDOX STRESS, PHOSPHOLIPID OXIDATION AND PULMONARY FIBROSIS

The major goal of this project is to understand the role of oxidized phospholipids (GPX4 deficiency) in modifying surfactant protein, ER stress and pulmonary fibrosis

Role: MPI  
Total cost \$429,000

**NIFA-USDA Sustainable Shukla (Co-PI), (PI Debra Neher)**  
Agriculture Systems  
Program 2019-08275

7/1/20-6/30/25

Emerging agricultural contaminants: Using microbiomes to characterize impacts on agricultural sustainability, resilience and wellbeing

Role Co-PI  
Total cost \$9,922,057

**RO1 Shukla (PI)**  
**NIH/NIEHS, ViCTER grant**

8/1/2021-7/31/2024

Airborne per and polyfluoroalkyle substances (PFAS) exposures and lung diseases

Role PI  
Total Cost \$ 1,848,029

**NCI-SBIR**, white paper submitted

## Pending

**W81XWH-22-TERP-IIRA; DoD-Toxic Exposures Research Program (TERP)  
Per- and Polyfluoroalkyl Substances (PFAS) and Lung Diseases**

## Patents and Publications:

### Patents:

1. A process for preparation of 3-(2-morpholin-4-yl) ethyl) amino-1-hex-ene-one-hydroxy-(1-[2-morpholin-4-yl) ethyl] pyrrolidin-2-yl)-1-aryl-1-oxo-ethyl-dene from 1-aryl-6-hex-2-ene-1-one-3-hydroxy as a therapeutic agent. Patent application No. 2711/DEL/98. **Granted** 3/16/04, no. 190787.
2. A process for preparation of 1-aryl-3-aminoalkyl (N,N-disubstituted) amino-hex-2-ene-1-one-6-hydroxy as a therapeutic agent. Patent application No. 2714/DEL/98. **Granted** 3/15/04, no. 190789
3. A process for preparation of 1-aryl-3-amino/aminoalkyl (N,N-disubstituted) amino-hex-2-ene-1-one-6-hydroxy as a therapeutic agent. Patent application No. 2715/DEL/98. **Granted** 4/12/04, no. 191084.
4. An International Patent for wound healing activity of Compound 93/637.

### Publications

**Total number of publications:** 105 (Original Peer-reviewed Research Articles= 77, Reviews= 16, Editorial=1, Book chapters & Monographs=8, Encyclopedia=1, Commentary=1, Report=1).  
\*Senior author=39.

**Peer-Reviewed Original Research Publications:** (Google scholar citation 7498; hi-index 45)

I have published 77 peer-reviewed original research papers. I am first author on 31 papers and the corresponding author on 39 papers.

My Bibliography: <https://www.ncbi.nlm.nih.gov/myncbi/arti.shukla.1/bibliography/public/>

\*The publications below in which **Arti Shukla is a corresponding author are marked with an asterisk (\*)**.

### Research papers

1. **Shukla A**, Agarwal KN, Chansuria JPN, Taneja V. Effect of latent iron deficiency on 5-hydroxytryptamine metabolism in rat brain. **Journal of Neurochemistry** 52, 730-735 (1989). (Impact factor 3.99) (Performed all experiments, analyzed data and wrote the manuscript).
2. \***Shukla A**, Agarwal KN, Shukla GS. Latent iron deficiency alters  $\gamma$ -aminobutyric acid and glutamate metabolism in rat brain. **Experientia** 45, 343-345 (1989). New name **Cellular and**

- Molecular Life Sciences.** Impact factor 6.09.(Performed experiments, analyzed data and wrote the manuscript, corresponding author)
3. **Shukla A**, Agarwal KN, Shukla GS. Effect of latent iron deficiency on metal levels of rat brain regions. **Biological Trace Element Research** 22, 141-152 (1989).Impact factor 1.13 (Performed experiments, analyzed data and wrote the manuscript).
  4. \***Shukla A**, Agarwal KN, Shukla GS. Rat brain catecholamines in latent iron deficiency. **Nutrition Research** 9,1177-1186 (1989). Impact factor, 1.2. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
  5. \***Shukla A**, Agarwal KN, Shukla GS. Effect of latent iron deficiency on the levels of iron, calcium, zinc, copper, manganese, cadmium and lead in liver, kidney, and spleen of growing rats. **Experientia**, 46, 751-752 (1990). New name **Cellular and Molecular Life Sciences**. Impact factor 6.09. (Performed experiments, analyzed data and wrote the manuscript, corresponding author)
  6. Radin NS, **Shukla A**, Shukla GS, Sano A. Heat stable protein that stimulates acid  $\alpha$ -glucosidase. **Biochemical Journal** 264, 845-849 (1989). Impact factor, 5.16. (Performed experiments).
  7. **Shukla A** and Radin NS. Metabolism of D-(<sup>3</sup>H)D-PDMP, an inhibitor of glucosylceramide synthesis, and the synergistic action of an inhibitor of microsomal monooxygenase. **Journal of Lipid Research**, 32, 713-722 (1991). Impact factor, 4.92. (Performed all experiments and analyzed data).
  8. Shukla GS, **Shukla A**, Radin NS. Gangliosides inhibit glucosylceramide synthase: a possible role in ganglioside therapy. **Journal of Neurochemistry** 56, 2125-2132 (1991). (Impact factor 3.99). (Performed experiments).
  9. Shukla GS, **Shukla A**, Inokuchi JI, Radin NS. Rapid kidney changes resulting from glycosphingolipid depletion by treatment with glucosyltransferase inhibitor. **Biochem Biophys Acta**, 1083, 101-108 (1991). Impact factor 4.36. (Performed experiments)
  10. **Shukla A**, Shukla GS and Radin NS. Control of kidney size by sex hormones: possible involvement of glucosylceramide. **American Journal of Physiology** 262, F24-F29 (1992). Impact factor 3.73. (Performed experiments and analyzed data).
  11. \***Shukla A**, Shukla R, Dikshit M, Srimal RC. Alterations in free radical scavenging mechanisms following blood-brain barrier disruption. **Free Radical Biology & Medicine** 15 (1), 97-100 (1993). Impact factor 6.08. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
  12. \***Shukla A**, Dikshit M, Srimal RC. Status of bioantioxidants in brain microvessels of monkey and rat. **Free Radical Research** 22 (4), 303-308 (1995). Impact factor 2.22. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
  13. \***Shukla A**, Dikshit M, Srimal RC. Involvement of nitric oxide in regulation of blood-brain barrier permeability in inactivated bacterium-treated rat. **Neuro-Report** 6(12), 1629-1632, (1995). Impact factor 1.81. (Performed experiments, analyzed data and wrote the manuscript, corresponding author)

14. \***Shukla A**, Dikshit M, Srimal RC. Nitric oxide dependent blood-brain barrier permeability alteration in the rat brain. **Experientia** 52, 136-140, (1996). New name, **Cellular and Molecular Life Sciences**. Impact factor 6.496. (Performed experiments, analyzed data and wrote the manuscript, corresponding author)
15. **Shukla A**, Dikshit M, Srimal RC. Cadmium induced alterations in blood-brain barrier permeability and its possible correlation with decreased microvessel antioxidant potential in rat. **Human and Experimental Toxicology** 15, 400-405, (1996). Impact factor 2.06 (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
16. Rasik AM, **Shukla A**, Patnaik GK, Kulshrestha DK, Srivastwa S, Dhawan BN. Wound healing activity of Euphorbia neriifolia. **Indian Journal of Pharmacology** 28, 07-109, (1996). (Performed experiments and wrote the manuscript)
17. \***Shukla A**, Rasik AM, Patnaik GK. Depletion of reduced glutathione, vitamin E and antioxidant defense enzymes in a healing cutaneous wound. **Free Radical Research** 26, 93-101 (1997). Impact factor 2.77. (Performed experiments and wrote the manuscript, corresponding author).
18. Kundu B, Singh G, Jain GK, **Shukla A**, Srivastava N and Patnaik GK. Wound healing activity of some novel analogues related to growth hormone releasing hexapeptide. **Protein and Peptide Letters** 5, 83-86 (1998). Impact factor 1.76. (Performed experiments).
19. **Shukla A**, Srivastava R, Dube MP, Srivastava BS. Molecular mechanism in healing of normal and delayed type of wounds: Role of new or over-expressed proteins. **Biochemical Biophysical Research Communication** 244, 434-439 (1998). Impact factor 2.985. (Performed experiments and analyzed data).
20. \***Shukla A**, Rasik AM and Shanker R. Nitric oxide inhibits wound collagen synthesis. **Molecular and Cellular Biochemistry** 200, 27-33 (1999). Impact factor 2.795. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
21. \***Shukla A**, Rasik AM, Jain GK, Shanker R, Kulshreshtha DK, Dhawan BN. In vitro and in vivo wound healing activity of asiaticoside isolated from *Centella asiatica*. **J. Ethnopharmacology** 65, 1-11 (1999). Impact factor 3.520. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
22. \***Shukla A**, Rasik AM, Dhawan BN. Asiaticoside-induced elevation of antioxidant levels in healing wounds. **Phytotherapy Research** 13, 50-54 (1999). Impact factor 3.880. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
23. Rasik AM, Raghubir R, Gupta A, **Shukla A**, Dube MP, Srivastava S, Jain HK and Kulshrestha DK. Healing potential of *Calotropis procera* on dermal wounds in guinea pigs. **J. Ethnopharmacology** 68, 261-266 (1999). Impact factor 3.520. (Performed experiments).
24. \*Rasik AM, **Shukla A**. Antioxidant status in delayed healing type of wounds. **International Journal of Experimental Pathology** 81, 257-263 (2000). Impact factor 2.04. (Designed all experiments and wrote the manuscript, corresponding author).

25. Hart BA, Lee CH, Shukla GS, **Shukla A**, Osier M, Eneman JD, Chiu JF. Characterization of cadmium-induced apoptosis in rat lung epithelial cells: evidence for the participation of oxidant stress. **Toxicology** 133, 43-58 (1999). Impact factor 3.24. (Performed experiments and analyzed data).
26. Shukla GS, **Shukla A**, Potts RJ, Ozier M, Hart BA, Chiu JF. Cadmium-mediated oxidative stress in alveolar epithelial cells induces the expression of gamma-glutamylcysteine synthetase catalytic subunit and glutathione S-transferase alpha and pai isoforms: Potential role of activator Protein-1. **Cell Biol & Toxicol** 16, 347-362 (2000). Impact factor 2.338. (Performed experiments and analyzed data).
27. **Arti Shukla**, C. Timblin, K. BeruBe, T. Gordon, W. McKinney, K. Driscoll, P. Vacek and B. T. Mossman. Airborne particulate matter causes expression of nuclear factor-kB-related genes after inhalation. **Am J Respir Cell Mol Biol** 23, 182-187 (2000). Impact factor 5.373. (Performed experiments and analyzed data).
28. B. T. Mossman, A. Hubbard, **Arti Shukla** and C. R. Timblin. Role of mitogen-activated protein kinases, early response protooncogenes, and activator protein-1 in cell signaling by asbestos. **Inhal Toxicol** 12 (suppl. 3), 307-316 (2000). Impact factor 3.20. (Performed experiments and analyzed data).
29. **Arti Shukla**, C.R. Timblin, A. Hubbard, J. Bravman and Brooke T. Mossman. Silica-induced activation of c-jun-NH<sub>2</sub>-terminal amino kinases, protracted expression of the activator protein-1 protooncogene, fra-1, and S-phase alterations are mediated via oxidative stress. **Cancer Res** 61 (5), 1791-1795 (2001). Impact factor 9.727. (Performed experiments and analyzed data).
30. C. Timblin, **Arti Shukla**, I. Berlanger, K. A. BeruBe, A. Churg and B.T. Mossman. Ultrafine airborne particles cause increases in protooncogene expression and proliferation in alveolar epithelial cells. **Toxicol. Appl. Pharmacol.** 179, 98-104 (2002). Impact factor 3.740. (Performed experiments and analyzed data).
31. A.K. Hubbard, C. R. Timblin, **Arti Shukla**, M. Rincon, B.T. Mossman. Activation of NF-kB-dependent gene expression by silica in lungs of luciferase reporter mice. **Am J Physiol Lung Cell Mol Physiol** 282, L968-L975 (2002). Impact factor 4.04. (Performed experiments and analyzed data).
32. **Arti Shukla**, M. Jung, M. Stern, N. K. Fukagawa, D.J. Taatjes, D. Sawyer, B. Van Houten and B.T. Mossman. Asbestos induces mitochondrial DNA damage and dysfunction linked to the development of apoptosis. **Am J Physiol (Lung Cell Mol. Physiol)** 285, L1018-25, (2003). Impact factor 4.04. (Performed experiments, analyzed data and wrote the manuscript).
33. M. Li, B. T. Mossman, E. Kolpa, C. R. Timblin, **Arti Shukla**, D. J. Taatjes and N. K. Fukagawa. Age-related differences in MAP kinase activity in VSMC in response to glucose or TNF-alpha. **J Cell Physiol.** 197, 418-425 (2003). Impact factor 4.59. (Intellectual input in designing experiments).
34. **Arti Shukla**, M. Stern, K. M. Lounsbury, T. Flanders and B.T. Mossman. Asbestos-induced apoptosis is protein kinase C delta dependent. **Am J Resp Cell Mol Biol**, 29,198-205 (2003). Impact factor 5.373. (Performed experiments, analyzed data and helped in writing the manuscript).

35. **Arti Shukla**, Pamela Vacek and Brooke T. Mossman. Dose response relationships in expression of biomarkers of cell proliferation in In vitro assays and inhalation experiments. **Nonlin. Biol. Toxicol Med**, 2, 117-128, **2004**. (Performed experiments).
36. **Arti Shukla**, Trisha Flanders, Karen M. Lounsbury and Brooke T. Mossman. Gamma-glutamylcysteine synthetase and glutathione regulate asbestos-induced expression of activator protein-1 family members and activity. **Cancer Research**, 64, 7780-7786, **2004**. Impact factor 9.727. (Performed experiments, analyzed data and wrote the manuscript).
37. Christy Barlow, **Arti Shukla**, Brooke T Mossman and Karen M. Lounsbury. Oxidant-mediated cAMP response element binding protein activation. Calcium regulation and role in apoptosis of lung epithelial cells. **Am J Resp. Cell Mol Biol**, 34, 7-14, **2006**. Impact factor 5.373. (Intellectual input in designing and performing experiments).
38. **Arti Shukla**, Trisha F. Barrett, Keiichi I. Nakayama, Keiko Nakayama, Brooke T. Mossman and Karen M. Lounsbury. Transcriptional upregulation of MMPs 12 and 13 by asbestos occurs via a PKC $\delta$ -dependent pathway in murine lung. **FASEB J**, 20, 1-10, **2006**. Impact factor 4.966. (Performed experiments, analyzed data and wrote the manuscript).
39. **Arti Shukla**, Karen M. Lounsbury, Trisha F. Barrett, Joanna J. Gell, Mercedes Rincon, Kelly J. Butnor, Douglas J. Taatjes, Gerald S. Davis, Pamela Vacek, Keiichi I. Nakayama, Keiko Nakayama, Chad Steele and Brooke T. Mossman. Asbestos-induced peribronchiolar cell proliferation, cytokine production, and fibrosis are attenuated in lungs of protein kinase C $\delta$  (PKC $\delta$ ) knockout mice. **Am J Pathol**, 170, 140-151, **2007**. Impact factor 5.67. (Performed experiments, analyzed data and wrote the manuscript).
40. Astrid Haegens, Trisha F. Barrett, Joanna Gell, **Arti Shukla**, Maximilian MacPherson, Pamela Vacek, Mathew E. Poynter, Kelly J. Butnor, Yvonne M. Janssen-Heininger, Chad Steele and Brooke T. Mossman. Airway epithelial NF $\kappa$ B activation modulates asbestos-induced inflammation and mucin production in vivo. **J Immunol**, 178 (3): 1800-1808 **2007**. Impact factor 5.65. (Designed Ribonuclease protection Assay construct).
41. Christy A. Barlow, Trisha F. Barrett, **Arti Shukla**, Brooke T. Mossman and Karen M. Lounsbury. Asbestos-mediated CREB phosphorylation is regulated by protein kinase A and Extracellular regulated kinases  $\frac{1}{2}$ . **Am. J. Physiol. Lung Cell Mol. Physiol**, 292: L1361-L1369, **2007**. Impact factor 4.04. (Intellectual input).
42. **\*Arti Shukla**, Maximilian MacPherson, Jedd Hillegass, Maria Ramos-Nino, Vlada Alexeeva, Pamela Vacek, Jeffrey Bond, Harvey Pass, Chad Steele and Brooke T Mossman. Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. **Am J Respir Cell Mol Biol**, 41, 114-123, **2009**. Impact factor 5.373 (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
43. Buder-Hoffmann SA, **Shukla A**, Barrett TF, MacPherson MB, Lounsbury KM, and Mossman BT: A PKC delta-dependent PKD pathway modulates ERK1/2 and JNK1/2 phosphorylation and Bim-associated apoptosis by asbestos. **Am J Pathol** 174:449-459, **2009**. Impact factor 5.67. (Intellectual input).
44. **\*Arti Shukla**, Marcus W. Bosenberg, Maximilian B MacPherson, Kelly J Butnor, Nicholas H Heintz, Harvey I. Pass, Michele Carbone, Joseph R. Testa and Brooke T. Mossman.

- Activated CREB is overexpressed in human mesotheliomas and inhibits apoptosis. **Am J Pathol.** 175: 2197-2206, **2009**. Impact factor 5.67. (Performed experiments, analyzed data and wrote the manuscript, corresponding author).
45. Jedd M. Hillegass, **Arti Shukla**, Maximilian B. MacPherson, Jeffrey P. Bond, Chad Steele and Brooke T. Mossman. Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1). **Journal of Toxicology and Environmental Health** 73: Part A, 1-15, **2010**. Impact factor 1.72. (Performed experiments and analyzed data).
  46. Hillegass, J.M., **Shukla, A**, Lathrop, S.A, MacPherson, M.B, Stacie L Beuschel, Kelly J Butnor, Joseph R. Testa, Harvey I. Pass, Michele Carbone, Chad Steele and Brooke T. Mossman. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. **Annals of the New York Academy of Sciences**, 1203, 7-14, **2010**. Impact factor 4.364. (Intellectual input).
  47. Jedd M. Hillegass, **Arti Shukla**, Maximilian B. MacPherson, Sherrill A. Lathrop, Vlada Alexeeva, Timothy N. Perkins, Albert van der Vliet, Pamela Vacek, Mickey E. Gunter, and Brooke T. Mossman. Mechanisms of oxidative stress and alterations in gene expression by Libby Six-Mix in human mesothelial cells. **Particle and Fiber Toxicology.** **2010** Sep 11;7: 26. Impact factor 9.18. (Designed experiments, analyzed data, intellectual input).
  48. Hillegass JM, Blumen SR, Cheng K, Macpherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Niño ME, **Shukla A**, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, Mossman. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. **Int J Cancer.** 129, 133-44. **2011** Impact factor 6.198. (Intellectual input).
  49. \***Arti Shukla**, Jedd M. Hillegass, Maximilian B. MacPherson, Stacie L. Beuschel, Pamela M. Vacek, Kelly J. Butnor, Harvey I. Pass, Michele Carbone, Joseph R. Testa, Nicholas H. Heintz and Brooke T. Mossman. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. **Int J Cancer.** 129, 1075-86, **2011** Impact factor 6.198. (Designed and performed experiments, analyzed data and wrote the manuscript, corresponding author). NIHMSID # 257610
  50. \***Arti Shukla**, Jedd M. Hillegass, Maximilian B. MacPherson, Stacie L. Beuschel, Pamela M. Vacek, Harvey I. Pass, Michele Carbone, Joseph R. Testa, and Brooke T. Mossman. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. **Mol Can.** 9, 314, **2010**. Impact factor 15.31. PMCID: PMC3016286. (Designed and performed experiments, analyzed data and wrote the manuscript, corresponding author).
  51. **Shukla A**, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass, HI, Faux SP, and Mossman BT: An ERK2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. **Am J Respir Cell Mol Biol**, **2011** Mar 31 PMCID: PMC3262687. Impact factor: 5.373. (contributed and analyzed data and intellectual input).
  52. Perkins TN, **Shukla A**, Peeters PM, Steinbacher JL, Landry CC, Lathrop SA, Steele C, Reynaert NL, Wouters EFM, and Mossman BT: Differences in gene expression and cytokine production by crystalline vs. amorphous silica in human lung epithelial cells. <http://www.particleandfibretoxicology.com/content/9/1/6> **Part Fibre Toxicol** 9:6, **2012**

PMCID: PMC3337246. Impact factor 9.18 (Analyzed data, intellectual input).

53. Newick K, Cunniff B, Preston K, Held P, Arbiser J, Pass H, Mossman BT, **Shukla A**, and Heintz N: Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. **PLoS One** 7:e39404, **2012** PMCID: PMC3382597  
Impact factor (2012): 3.73 (Provided material and intellectual input).
54. Macura SL, Hillegass JM, Steinbacher JL, MacPherson MB, **Shukla A**, Beuschel SL, Perkins TN, Butnor KJ, Lathrop MJ, Sayan M, Hekmatyar K, Taatjes DJ, Kauppinen RA, Landry CC, and Mossman BT: A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas. **J Histochem Cytochem** 60(9):658-674, **2012** PMCID: PMC3524557.  
Impact factor (2012): 2.25  
(Intellectual input).
55. \***Shukla A**, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL, Hillegass JM, Vacek PM, Pass HI, and Mossman BT: Extracellular signal regulated kinase 5: a potential therapeutic target for malignant mesotheliomas. **Clin Cancer Res** 19:2071-2083, **2013** PMCID: PMC3630261. Impact factor: 10.107  
(Conceived the idea, performed experiments, analyzed data, interpreted results, and wrote the manuscript. Corresponding author).
56. Macura SL, Steinbacher JL, MacPherson MB, Lathrop MJ, Sayan M, Hillegass JM, Beuschel SL, Perkins TN, Spiess PC, van der Vliet A, Butnor KJ, **Shukla A**, Wadsworth M, Landry CC, and Mossman BT: Microspheres targeted with a mesothelin antibody and loaded with Doxorubicin reduce tumor volume of human mesotheliomas in xenografts. **BMC Cancer** 13, 400, **2013**. Impact factor (2012): 3.33  
PMCID: PMC3846908. (Designed experiments and intellectual input)
57. \*Hillegass JM, Miller JM, MacPherson MB, Catherine Westbom, Sayan M, Thompson JK, Macura SL, Perkins TN, Beuschel SL, Alexeeva V, Pass HI, Steele C, Mossman BT, and **Shukla A**: Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. **Particle and Fiber Toxicology**, 10, 39, **2013**. PMCID: PMC3751315.  
Impact factor (2012): 9.18. (Conceived the idea, performed experiments, analyzed data, interpreted results, and wrote the manuscript. Corresponding author).
58. \*Jill Miller, Joyce Thompson, Maximilian MacPherson, Catherine Westbom, Mutlay Sayan, Stacie Beuschel and **Arti Shukla**. Curcumin: A double hit on malignant mesothelioma. **Cancer Prevention Research (AACR)**, 7, 330-40, **2014**. PMCID: PMC3951553. Impact factor: 4.891  
Role: conceived the idea, planned experiments, supervised experiments, interpreted data, reviewed the manuscript and was corresponding author.
59. Sayan Mutlay, **Shukla Arti**, MacPherson Maximilian, Macura Sherrill, Hillegass Jedd, Jill Miller, Perkins Timothy, Thompson Joyce, Beuschel Stacie, and Mossman Brooke. ERK5 and CREB are Novel Pathways Inhibited by Vandetanib (ZD6474) and Doxorubicin in Mesotheliomas. **Am J Resp Cell Mol Biol**. 51, 595-603, **2014**. Impact factor (2012): 5.373.  
Contributed data, intellectual input.



60. \*Thompson K Joyce, Westbom M Catherine, MacPherson B Maximilian, Mossman T Brooke, Heintz H Nicholas, Spiess Page, **Shukla Arti**. Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. **Particle and Fibre Toxicology** 11(1):24. doi: 10.1186/1743-8977-11-24, **2014**. PMID: PMC4055279, Impact factor (2013): 9.18.  
Designed and performed experiments, analyzed data, wrote the manuscript and corresponding author
61. \*Catherine Westbom, Anurag Shukla, Maximilian Macpherson, Elizabeth C. Yasewicz, Jill M. Miller, Stacie L. Beuschel, Chad Steel, Harvey I. Pass, Pamela M. Vacek and **Arti Shukla**. CREB-induced inflammation is important for malignant mesothelioma growth. **American Journal of Pathology**, 184, 2816-27, **2014**.  
Designed and performed experiments, analyzed data, wrote the manuscript and corresponding author.  
**This article was showcased on *The American Journal of Pathology's* Facebook page (<https://www.facebook.com/AJPathology>) and on Twitter @AJPathology.**
62. Lathrop MJ, Sage EK, Macura SL, Brooks EM, Bonenfant NR, Sokocevic D, MacPherson MB, Beuschel SL, Dunaway CW, **Shukla A**, Janes SM, Steele C, Mossman BT, Weiss DJ. Mesenchymal Stromal Cells Expressing TRAIL Inhibit Tumor Growth and Alter the Tumor Microenvironment of Human Malignant Mesotheliomas in a Mouse Xenograft Model. **Cancer Gene Therapy**, 22, 44-54, **2015**.  
Role: Designed experiments, interpreted data, contributed stable cell lines and intellectual input.
63. Timothy N Perkins, Paul M Peeters, **Arti Shukla**, Ingrid Arijs, Julie Dragon, Emiel FM Wouters, Niki L Reynaert, Brooke T Mossman. Indications for distinct pathogenic mechanisms of asbestos and silica through gene expression profiling of the response of lung epithelial cells. **Human Molecular Genetics**, **2014**. 2015 Mar 1;24(5):1374-89 PMID:25351596. Contributed data.
64. Sameer Kaiser MD, Maximilian B MacPherson, Page Spiess PhD, Albert Emery, Albert van der Vliet PhD, Ted James MD FACS, Christopher C Landry PhD, **Arti Shukla** PhD. Exploratory use of Docetaxel Loaded Acid-Prepared Microporous Spheres for the Treatment of Malignant Melanoma. **Cancer Nanotechnology**, 6, 1-8 **2015**. Intellectual input, contributed data, reviewed the manuscript.
65. \*Julie Dragon, Joyce Thompson, Maximilian Macpherson and **Arti Shukla**. Differential susceptibility of human pleural and peritoneal mesothelial cells to asbestos exposure. **J Cell. Biochem.** 2015 Aug;116(8):1540-52. PMID:25757056. Supervised the study, designed experiments, trouble shot, reviewed and edited the manuscript.
66. Brian Cunniff, PhD; Kheng Newick; Kimberly J Nelson; Stacie Beuschel; Bruce Leavitt; Anant Bhave; Kelly Butnor; Alexandra Wozniak; Andreas Koenig; Edward Chouchani; Andrew James; Todd Lowther; Michael Murphy; **Arti Shukla**; Nicholas Heintz. Disabling mitochondrial peroxide metabolism via combinatorial targeting of peroxiredoxin 3 as effective therapeutic approach for malignant mesothelioma. **PLoS One**, **2015** May 26;10(5):e0127310. doi: 10.1371/journal.pone.0127310. eCollection 2015. Intellectual input.  
**This paper won 2015 Norman R Alpert Research Prize (CMB).**

67. \*Catherine Westbom, Joyce Thompson, Alan Leggett, Maximilian MacPherson, Stacie Beuschel, Pamela Vecek, Harvey Pass and **Arti Shukla**. Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma. **PLoS One**, 2015 Dec 21;10(12):e0145404. doi: 10.1371/journal.pone.0145404. eCollection 2015. Supervised the study, designed experiments, generated data, trouble shot, wrote, reviewed and edited the manuscript.
68. Yuwaraj Kadariya, Craig W. Menges, Jacqueline Talarchek, Kathy Q. Cai, Andres J. Klein-Szanto, Ralph A. Pietrofesa, Melpo Christofidou-Solomidou, Mitchell Cheung, Brooke T. Mossman, **Arti Shukla**, and Joseph R. Testa. Inflammation-Related IL-1 $\beta$ /IL-1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. **Cancer Prevention Research**, 2016, 9 (5), 406-414: canprevres.0347.2015. PMID: 26935421. Intellectual input, reviewed the manuscript.  
**(This article was one of the most highly cited *Cancer Prevention Research* articles published in 2016).**
69. \*Maximilian MacPherson, Catherine Westbom, Helena Kogan and **Arti Shukla**  
Actin polymerization plays a significant role in asbestos-induced inflammasome activation in mesothelial cells in vitro. **Histochemistry and Cell Biol.** 147 (5), 595-604, 2017. Dec 24. PMID:28013367. Supervised the study, designed experiments, trouble shot, wrote, reviewed and edited the manuscript.
70. \*Joyce Thompson, Maximilian MacPherson, Stacie Beuschel and **Arti Shukla**. Asbestos-induced mesothelial to fibroblastic transition is modulated by the inflammasome. **Am J Pathol.** 2017,187, 665-678. PMID: 28056339. Supervised the study, designed experiments, trouble shot, reviewed and edited the manuscript.
71. \*Joyce K. Thompson, Anurag Shukla, Alan L. Leggett, Phillip B. Munson, Jill M. Miller, Maximilian B. MacPherson, Stacie L. Beuschel, Harvey I. Pass and **Arti Shukla**. Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma. **Oncotarget.** 2017 Dec 6; 9:293-305.PMID: 29416614 PMCID: PMC5787465 <https://doi.org/10.18632/oncotarget.22968>. Supervised the study, designed experiments, trouble shot, reviewed and edited the manuscript.  
**This paper was promoted/showcased on UVMCC social media, Feb 12, 2018.**  
[www.vermontcancer.org](http://www.vermontcancer.org)
72. \*Phillip Munson, Ying-Wai Lam, Julie Dragon, Maximilian MacPherson, and **Arti Shukla**. Exosomes from asbestos exposed cells modulate gene expression in mesothelial cells. **FASEB J**, 32, 2018. PMID 29553831. Supervised the study, designed experiments, trouble shot, reviewed and edited the manuscript.  
doi: 10.1096/fj.201701291RR <http://www.fasebj.org/doi/10.1096/fj.201701291RR>  
Selected by FASEB for promotion to the news media via press release.  
Press release: [https://www.eurekalert.org/pub\\_releases/2018-03/foas-fjn031218.php](https://www.eurekalert.org/pub_releases/2018-03/foas-fjn031218.php)  
ATI news report: <http://allthatsinteresting.com/asbestos-detection>  
College of medicine:  
[http://www.med.uvm.edu/com/news/2018/03/27/shukla\\_research\\_highlights\\_how\\_asbestos\\_causes\\_lung\\_disease\\_mesothelioma](http://www.med.uvm.edu/com/news/2018/03/27/shukla_research_highlights_how_asbestos_causes_lung_disease_mesothelioma)
73. \*Munson, Phillip; Lam, Ying-Wai; MacPherson, Maximilian; Beuschel, Stacie; **Shukla, Arti**. Mouse serum exosomal proteomic signature in response to asbestos exposure. **J Cell Biochem** 2018. DOI: 10.1002/jcb.26863. (Epub ahead of print). PMID 29663493. Supervised the study, designed experiments, trouble shot, reviewed and edited the manuscript.

74. Lisbeth Berrueta, Johann Bergholz, Dennis Munoz, Iгла Muskaj, Gary Badger, **Arti Shukla**, Hye-Jung KIm, Jean Zhao and Helene Langevin,. Stretching reduces tumor growth in a mouse breast cancer model. **Scientific Reports**, 2018, 8, 7864. DOI: 10.1038/s41598-018-26198-7. Contributed data, reviewed the manuscript.

Press release: [https://www.genengnews.com/gen-news-highlights/yoga-like-exercise-associated-with-smaller-tumors-in-breast-cancer/81255846/?utm\\_medium=newsletter&utm\\_source=gen+daily+news+highlights&utm\\_content=01&utm\\_campaign=gen+daily+news+highlights\\_20180523&ajs\\_trait\\_oebid=9675b9130356b7s](https://www.genengnews.com/gen-news-highlights/yoga-like-exercise-associated-with-smaller-tumors-in-breast-cancer/81255846/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20180523&ajs_trait_oebid=9675b9130356b7s)

75. \*Munson P, Hall EM, Farina NH, Pass HI, and **Shukla A**. Exosomal miR16-5p as potential target for malignant mesothelioma. **Scientific Reports** 2019 Aug 12;9(1):11688. doi: 10.1038/s41598-019-48133-0. PMID: 31406207  
Supervised the study, designed experiments, trouble shot, reviewed and edited the manuscript.

76. Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, Mark MT, Steiner L, Benito-Martin A, Lucotti S, Di Giannatale A, Offer K, Nakajima M, Williams C, Nogués L, Pelissier Vatter FA, Hashimoto A, Davies AE, Freitas D, Kenific CM, Ararso Y, Buehring W, Lauritzen P, Ogitali Y, Sugiura K, Takahashi N, Alečković M, Bailey KA, Jolissant JS, Wang H, Harris A, Schaeffer LM, García-Santos G, Posner Z, Balachandran VP, Khakoo Y, Raju GP, Scherz A, Sagi I, Scherz-Shouval R, Yarden Y, Oren M, Malladi M, Petriccione M, De Braganca KC, Donzelli M, Fischer C, Vitolano S, Wright GP, Ganshaw L, Marrano M, Ahmed A, DeStefano J, Danzer E, Roehrl MHA, Lacayo NJ, Vincent TC, Weiser MR, Brady MS, Meyers PA, Wexler LH, Ambati SR, Chou AJ, Slotkin EK, Modak S, Roberts SS, Basu EM, Diolaiti D, Krantz BA, Cardoso F, Simpson AL, Berger M, Rudin CM, Simeone DM, Jain M, Ghajar CM, Batra SK, Stanger BZ, Bui J, Brown KA, Rajasekhar VK, Healey JH, de Sousa M, Kramer K, Sheth S, Baisch J, Pascual V, Heaton TE, La Quaglia MP, Pisapia DJ, Schwartz R, Zhang H, Liu Y, **Shukla A**, Blavier L, DeClerck YA, LaBarge M, Bissell MJ, Caffrey TC, Grandgenett PM, Hollingsworth MA, Bromberg J, Costa-Silva B, Peinado H, Kang Y, Garcia BA, O'Reilly EM, Kelsen D, Trippett TM, Jones DR, Matei IR, Jarnagin WR, Lyden D.

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.

**Cell**. 2020 Aug 11:S0092-8674(20)30874-6. doi: 10.1016/j.cell.2020.07.009. Online ahead of print. PMID: 32795414

This article was highlighted in Cancer Discovery (AACR), News in Brief.

77. Julie Dragon, Michael Hoaglund, Appala Raju Badireddy, Greylin Nielsen, Jennifer Schlezinger and **Arti Shukla**. Perfluoroalkyl substances (PFAS) affect inflammation in lung cells and tissues. **IJMS**, 2023, 24, 8539; <https://doi.org/10.3390/ijms24108539>  
<https://pubmed.ncbi.nlm.nih.gov/37239886>

## **Report**

TSCA Science Advisory Committee on Chemicals Meeting Minutes and Final Report No. 2020-6 Peer Review of EPA Draft Risk Evaluation of Asbestos  
[https://scholar.google.com/citations?view\\_op=view\\_citation&hl=en&user=sE9x8IsAAAAJ&cst\\_art=100&pagesize=100&citation\\_for\\_view=sE9x8IsAAAAJ:gVv57TyPmFsC](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=sE9x8IsAAAAJ&cst_art=100&pagesize=100&citation_for_view=sE9x8IsAAAAJ:gVv57TyPmFsC)

June 8 -11, 2020.

Henry Anderson, Charles Barton, Steven Bennett, Sheri Blystone, Deborah Cory-Slechta, Holly Davies, William Doucette, Concepcion Jimenez-Gonzalez, Mark Johnson, Alan Kaufman, John Kissel, Sheela Sathyanarayana, Craig Rowlands, Daniel Schlenk, Kenny Crump, Jeffrey Everitt, Robert Herrick, SD Michael A Jayjock, Marty Kanarek, Steven Markowitz, Elizabeth A Lianne Sheppard, **Arti Shukla**, Emanuela Taioli

### Review articles

1. R. C. Simal and **Arti Shukla**. The blood-brain barrier: some recent developments. *Annals of Neurosciences* 6, 42-54 (1997).
2. P. Thakur, **Arti Shukla**, A. M. Rasik and G. K. Patnaik. Animal models for study of wound healing activity. *Laboratory Animals of India*, 4, 65-70, (1995).
3. **Arti Shukla**, and G. K. Patnaik. Wound healing: Molecular mechanisms and search for agents promoting the process of healing. *Proceedings of National Academy of Science (India)* 67, 127-139 (1997).
4. **Arti Shukla**, N. Meisler and K.R. Cutroneo. TGF- $\beta$ : Cross road of bleomycin and glucocorticoid induced regulation of collagen synthesis. *Wound Repair and Regeneration* 7, 133-140 (1999).
5. M. E. Ramos-Nino, A. Hagens, **Arti Shukla** and B.T. Mossman. Role of mitogen-activated protein kinases (MAPK) in cell injury and proliferation by environmental particulates. *Mol. Cel. Biochem.* 234/235, 111-118 (2002).
6. **Arti Shukla**, M. Ramos-Nino, B.T. Mossman. Cell signaling and transcription factor activation by asbestos in lung injury and disease. *Int. J. Biochem Cell Biol.* 1439, 1-11 (2002).
7. **Arti Shukla**, M. Gulumian, T. Hei, D. Kamp, Q. Rahman, A. Aust and B. Mossman. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. *Free Radic Biol Med* 34, 1117-1129 (2003).
8. Hillegass, J.M., **Shukla, A.**, Lathrop, S.A., MacPherson, M.B., Fukagawa, N.K., and Mossman, B.T. Assessing nanotoxicity in cells in vitro. *Wiley Interdiscip Rev Nanomed Nanobiotechnol.* 2009 Sep 3. [Epub ahead of print]. NIHMS180808.
9. \*Joyce Thompson, Catherine Westbom and **A Shukla**, Malignant mesothelioma: development to therapy. *J Cellular Biochemistry*, **2013** Aug 19. doi: 10.1002/jcb.24642. [Epub ahead of print] (invited review).
10. \*Miller J and **Shukla A**: The role of inflammation in development and therapy of malignant mesothelioma (Invited review). *Am Med J* 3:240-248, **2012**.
11. Mossman BT, **Shukla A**, Heintz NH, Verschraegen CF, Thomas A, and Hassan R: New insights into understanding the mechanisms, pathogenesis, and management of malignant

mesotheliomas (Invited review). *Am J Pathol* 182:1065-1077, **2013** PMID: PMC3657618.

Impact factor: 5.67

12. \*Anurag Shukla and **Arti Shukla**. Current therapies for malignant mesothelioma. *Cancer Science and Therapy* 6: 306-309, **2014**.
13. Danielle J. Carlin; Theodore C. Larson; Jean C. Pfau; Stephen H. Gavett; **Arti Shukla**, Aubrey Miller; Ronald Hines. Current Research and Opportunities to Address Environmental Asbestos Exposures. *Environmental Health Perspective*, 123, **2015**, DOI:10.1289/ehp.1409662.
14. \*Phillip Munson and **Arti Shukla**. Exosomes: Potential in Cancer Diagnosis and Therapy. *Medicines* 2015, 2, 310-327; doi:10.3390/medicines2040310
15. Evan A. Elko, Brian Cunniff, David J. Seward, Shi Biao Chia, Reem Aboushousha, Cheryl van de Wetering, Jos van der Velden, Allison Manuel, **Arti Shukla**, Nicholas H. Heintz, Vikas Anathy, Albert van der Vliet, and Yvonne M.W. Janssen-Heininger. Peroxiredoxins and beyond; redox systems regulating lung physiology and disease. *Antioxidants and Redox Signaling*, 2019 Apr 5. doi: 10.1089/ars.2019.7752. [Epub ahead of print]. PMID:30799628
16. Phillip Munson and **Arti Shukla**. Potential roles of exosomes in the development and detection of malignant mesothelioma: An update. *International J of Molecular Sciences*, 2022, 23, 15438 <https://doi.org/10.3390/ijms232315438>.

## Editorial

1. \*Thompson J and **Shukla A**: Asbestos risks: past and present (**editorial**). *Air Water Born Dis* 2(1), **2013**.

## Book Chapters

1. **Arti Shukla**, C. R. Timblin, B.T. Mossman and A. Hubbard. The role of free radicals in asbestos- and silica-induced fibrotic lung diseases. In: *Environmental Stressors in Health and Disease*. Eds: Jurgen Fuchs and Lester Packer. Marcel Dekker, Inc., New York, Basel. 2002
2. **Arti Shukla** and B.T. Mossman. Asbestosis and lung cancer: Role of reactive species, In; *Reactive Oxygen /Nitrogen Species: Lung Injury and Disease*, Eds. V.Vallyathan, V. Castranova and X. Shi. 187, 179-195, Marcel Dekker Inc, New York. Basel 2004.
3. \***Arti Shukla** and Brooke T. Mossman. Molecular mechanisms of environmental particulates in lung inflammation and fibrosis. In *Recent research Developments in Molecular and Cellular Biochemistry* (edited by S.G. Pandalai) vol.2 Part-1, 35-48, ISBN, Research Signpost, Trivendrum, Kerala, India, 2005.
4. Kelly Berube, Dominique Balharry, Tomothy Jones, Teresa Moreno, Patrick Hayden, Keith Sexton, Martina Hicks, Luciano Merolla, Cynthia Timblin, **Arti Shukla** and Brooke Mossman.

Characterization of airborne particulate matter and related mechanisms of toxicity: An experimental approach. WSPC/SPI-B409: Air Pollution and Health, Chapter 4, 69-110, 2006.

5. **Arti Shukla** and Brooke T. Mossman. Cell signaling by oxidants: Mitogen-activated protein kinases (MAPK) and Activator protein-1 (AP-1). In Current Topics in Membranes: Free radical effects on membranes, ed. Sadis Matalon. Vol. 61, chapter 9, 191-209, Elsevier, Academic Press. 2008.
6. \*Jill Miller, Joyce Thompson and **A. Shukla**. Asbestos-Induced Oxidative Stress in Lung Pathogenesis. In, Laher I (ed.), Systems Biology of Free Radicals and Anti-Oxidants, DOI 10.1007/978-3-642-30018-9\_201, # Springer-Verlag Berlin Heidelberg, Vol 3, pp 1587-1610, **2014**.
7. \*Joyce Thompson and **Arti Shukla**. Asbestos-induced inflammation in mesothelioma and other lung diseases. In, Asbestos and Mesothelioma, editor, Joseph Testa, series, Current Cancer Research, Springer International Publishing, 2017, pp 161-174. DOI 10.1007/978-3-319-53560-9\_7
8. \*Phillip B. Munson and **Arti Shukla**, Introduction to Exosomes and Cancer. In, Exosomes in Cancer: Diagnostic, Pharmaceutical and Therapeutic Applications" Edited by Ramesh and Amiji, Elsevier Press, 2018.

#### Encyclopedia chapter

1. \***Arti Shukla** and Brooke T. Mossman. Oxidants and Antioxidants: Oxidants. In, Encyclopedia of Respiratory Medicine (Edited by G J Laurent and SD Shapiro). 271-278, Vol 2, 2006 Elsevier Ltd.

#### Commentary

1. Brooke T. Mossman, **Arti Shukla** and Naomi Fukagawa. Commentary on "Oxidative stress and lipid mediators induced in alveolar macrophages by ultrafine particles", by Beck-Speier, N. Dayal, E. Karg, K.L. Maier, G. Schumann, H. Schulz, M. Semmler, S. Takenaka, K. Stettmaier, W. Bors, A. Ghio, J.M. Samet, J. Heyder. Free Rad Biol Med, 43: 504-505, 2007.

#### Other peer reviewed papers presented in international, national and local conferences/ symposia/abstracts published:

1. V. Taneja, **Arti Shukla**, V. Anand and K.N. Agrawal. Effects of prolonged iron-deficiency in dams on rat brain GABA shunt enzymes. In International Seminar on Structure and function of enzymes held 22<sup>nd</sup> to 25<sup>th</sup> October 1986 at Biochemistry Department, Faculty of Science, Banares Hindu University, Varanasi. (**Local**)
2. **Arti Shukla**, V. Taneja and K.N. Agarwal. Nutritional studies on laboratory animals. In the Symposium on Baseline Data on Laboratory Animals held on 19<sup>th</sup> to 20<sup>th</sup> March 1987 at Central Drug Research Institute, Lucknow. (**National**)
3. **Arti Shukla**, V. Anand, V. Taneja and K.N. Agarwal. Brain neurotransmitters and related enzymes in latent iron depletion. In 20<sup>th</sup> Annual Meeting of Nutrition Society of India, held on 6<sup>th</sup> & 7<sup>th</sup> November 1987 at the M.S. University, Baroda. **Won best presentation award. (National)**

4. **Arti Shukla**, G.S. Shukla and Norman S. Radin. Gangliosides inhibit brain glucosylceramide synthase. In 20th Annual Meeting of American Society for Neurochemistry, held on 5<sup>th</sup> to 9<sup>th</sup> March 1989 at Chicago, Illinois, USA. **(National)**
5. **Arti Shukla** and G.S. Shukla. Possible role of latent iron deficiency in lead and cadmium toxicity. In 11th Annual Meeting of the American College of Toxicology, held on 29<sup>th</sup> to 31<sup>st</sup> October 1990 at Orlando, Florida, USA. **(National)**
6. R. Shukla, **Arti Shukla**, M. Dikshit and R.C. Srimal. Do free radical scavenging enzymes have a role in maintaining the blood-brain barrier? Presented at First Asian Pacific Society for Neurochemistry, held on 22<sup>nd</sup> & 23<sup>rd</sup> October 1992 at Nagoya, Japan. **(International)**
7. **Arti Shukla** and R.C. Srimal. Free radical involvement in blood brain barrier disruption. In 25<sup>th</sup> Annual Conference of Indian Pharmacological Society (IPS) from 4<sup>th</sup> to 6<sup>th</sup> December 1992, at Muzaffarpur. **Abstract in Indian J. Pharmacol.25 (1), 38, 1993. (National)**
8. G.S. Shukla, **Arti Shukla** and R.C. Srimal. Cadmium induced effects on microvessel antioxidative defense system and their possible role in blood brain barrier damage. In 25<sup>th</sup> Annual Conference of Indian Pharmacological Society, held from 23<sup>rd</sup> to 28<sup>th</sup> December 1992, at Muzaffarpur. **Abstract in Indian J. Pharmacol. 25, (1), 38, 1993. (National)**
9. **Arti Shukla**, M. Dikshit and R. C. Srimal. Regulation of blood-brain barrier permeability by nitric oxide. In Meeting of International Union of Pharmacologists, held in July 1994 at Montreal, Canada. **Abstract in Can. J. Physiol. Pharmacol. 72 (suppl.1), 474, 1994. (International)**
10. **Arti Shukla**, M. Dikshit and R. C. Srimal. Role of nitric oxide in regulating the permeability of blood-brain barrier. In 26<sup>th</sup> Annual Conference of Indian Pharmacological Society from 25<sup>th</sup> to 27<sup>th</sup> November 1993, at Hisar. **Abstract in Ind. J. Pharmacol. 26, 70, 1994. (National)**
11. **Arti Shukla**, M. Dikshit and R. C. Srimal. Antioxidative potential of rat and monkey brain microvessels: a comparative study. In 27<sup>th</sup> Annual Conference of Indian Pharmacological Society, held from 21<sup>st</sup> to 24<sup>th</sup> December 1994, at Bombay. **Abstract in Ind. J. Pharmacol. 27, 79, 1995. Won best poster award. (National)**
12. A. M. Rasik, **Arti Shukla**, G. K. Patnaik, D. K. Kushrestha, S. Srivastava and B. N. Dhawan. Wound healing activity of Euphorbia nerifolia. Presented in 28<sup>th</sup> Annual Conference of Indian Pharmacological Society, held in November 1995 at Patiala. **Abstract in Ind. J. Pharmacol. (National)**
13. **Arti Shukla**, A. M. Rasik and G. K. Patnaik. Healing cutaneous wound: status of free radical scavengers. Presented at the 41<sup>st</sup> Annual National Conference of Association of Physiologists and Pharmacologists of India, held in December 1995 at Belgaum. **(National)**
14. **Arti Shukla**, A. M. Rasik and G.K. Patnaik. Does glutathione play a role in delayed healing of diabetic wounds? Studies on antioxidant profile of hyperglycemic rat skin. Presented at the 29<sup>th</sup> Annual Conference of Indian Pharmacological Society held at Deccan College of Medical Sciences, Hyderabad, India in December 1996. **Abstract in Ind. J. Pharmacol. (National)**

15. A. M. Rasik, **Arti Shukla**, G. K. Patnaik, D. K. Kulshrestha and B. N. Dhawan. Wound healing activity of *Centella asiatica*. Presented in 29<sup>th</sup> Annual Conference of Indian Pharmacological Society, held at Deccan College of Medical Sciences, Hyderabad, in December 1996. **Abstract in Ind. J. Pharmacol (National)**
16. **Arti Shukla**, C. Timblin, A. Cummins, D. Hemenway, K. BeruBe and B. Mossman. Ambient particulate matter (PM<sub>2.5</sub>) induces multiple signaling pathways in rodent alveolar type II epithelial cells. Presented in International Conference of American Thoracic Society, held in San Diego, California, April 1999. **Abstract published in the proceedings of ATS journal. (National)**
17. Timblin C, **Arti Shukla**, J. Bravman, A. Cummins and B. Mossman. Patterns of activator protein-1 (AP-1) and nuclear factor-kappa B (NFkB) transcription factor activation by silica and asbestos in a murine alveolar type II epithelial cell line (C10). Presented in International Conference of American Thoracic Society, held in San Diego, California, April 1999. **Abstract published in the proceedings of ATS journal. (National)**
18. Shukla G. S, **Arti Shukla**, M. Osier, J-F Chiu and B. A. Hart. Potential role of activator protein-1 in cadmium-induced alveolar epithelial gene expression of  $\gamma$ -glutamylcysteine synthetase and glutathione s-transferase isoforms. Presented in International Conference of American Thoracic Society, held in San Diego, California, April 1999. **Abstract published in the proceedings of ATS journal. (National)**
19. Timblin C, **Arti Shukla** and B. Mossman. Ambient particulate matter (PM<sub>2.5</sub>) induces dose-related changes in protooncogene and proapoptotic gene expression in murine alveolar type II epithelial cells. Presented in Third Colloquium on Particulate Air Pollution and Human health, held in Durham, North Carolina, June 6-8, 1999. **(National)**
20. Naomi k Fukagawa, M Li, C. Timblin, **Arti Shukla**, M Absher, B E Sobel and B T Mossman. Age related sensitivity to glucose-induced NFkB activation in vascular smooth muscle cells. Presented in 6<sup>th</sup> Annual Meeting of the Oxygen society, held from 18<sup>th</sup> to 22<sup>nd</sup> November 1999 at New Orleans, Louisiana, USA. **Abstract in Free Radical Biology and Medicine (National)**
21. **Arti Shukla**, C. Timblin, K. BeruBe, T. Gordon, W. Mckinney, K. Driscoll, P. Vacek and B.T. Mossman. Airborne particulate matter inhalation leads expression of nuclear factor-kB-related genes in mouse lung. Presented in International Conference on Environmental & Occupational Respiratory Diseases, held at Lucknow, India from 29<sup>th</sup> October to 2<sup>nd</sup> November 2000. **(Local)**
22. **Arti Shukla**, C.R. Timblin, A.K. Hubbard, J. Bravman and B.T. Mossman Silica-induced activation of c-jun-NH<sub>2</sub>-Terminal amino kinases, protracted expression of the activator protein-1 protooncogene, fra-1 and s-phase alterations are mediated via oxidative stress. Presented in International Conference on Environmental & Occupational Respiratory Diseases, held at Lucknow, India, from 29<sup>th</sup> October to 2<sup>nd</sup> November, 2000. **Won best presentation award. (Local)**
23. **Arti Shukla**, K. Lounsbury, M. Stern, T. Flanders and B. Mossman PKC delta selectively regulates asbestos-induced fra-1 transcription. Presented in 9<sup>th</sup> Annual Meeting of the Oxygen society, held from 20-24 November 2002 at San Antonio, TX, USA. **Selected oral presentation. Abstract in Free radical Biology and Medicine. (National)**



24. **Arti Shukla**, M. Stern, K. Lounsbury, T. Flanders and B. Mossman. Asbestos-induced apoptosis in mouse lung epithelial cells is PKC delta dependent. Presented in 9<sup>th</sup> Annual Meeting of the Oxygen society, held from 20-24 November 2002 at San Antonio, TX, USA. **Abstract in Free radical Biology and Medicine. (National)**
25. K. Lounsbury, M. Stern, **Arti Shukla** and B. Mossman PKC delta is required for H<sub>2</sub>O<sub>2</sub> and asbestos-induced MAPK activation and proliferation in lung epithelial cells. Presented in 9<sup>th</sup> Annual Meeting of the Oxygen society, held from 20-24 November 2002 at San Antonio, TX, USA. **Abstract in Free Radical Biology and Medicine. (National)**
26. M. Stern, **Arti Shukla**, K.M. Lounsbury, D.J. Taatjes and B.T. Mossman PKC delta is essential for asbestos-induced apoptosis and proliferation in lung epithelial cells. Presented in Meeting of Experimental Biology 2003, April 11-15, at San Diego, CA, USA. **Abstract in FASEB J. (National)**
27. M. Stern, **Arti Shukla**, K.M. Lounsbury, T.H. Flanders, D. J. Taatjes and B.T. Mossman. PKC delta regulates asbestos-induced ERK activation and fra-1 transcription. Presented in Meeting of Experimental Biology 2003, April 11-15, at San Diego, CA, USA. **Abstract in FASEB J. (National)**
28. Christy Barlow, **Arti Shukla**, Brooke Mossman and Karen Lounsbury. Oxidant signals leading to phosphorylation of ERK and CREB in lung epithelial cells: Different requirements for Ca influx. Presented in SFRBM's 10<sup>th</sup> Annual meeting, held at Seattle, WA from 20-24 November 2003. **Abstract in Free Radical Biology and Medicine. (National)**
29. Trisha Flanders, **Arti Shukla**, Karen Lounsbury and Brooke Mossman. Glutathione regulates asbestos-induced AP-1 protooncogenes. Presented in SFRBM's 10<sup>th</sup> Annual meeting, held at Seattle, WA from 20-24 November 2003. **Abstract in Free radical Biology and Medicine. (National)**
30. **Arti Shukla**, Trisha Flanders, Karen Lounsbury and Brooke Mossman. Asbestos exposure upregulates matrix metalloproteinases in epithelial cells and fibroblasts. Presented in SFRBM's 10<sup>th</sup> Annual meeting, held at Seattle, WA, from 20-24 November 2003. **Abstract in Free radical Biology and Medicine. (National)**
31. **Arti Shukla** Health issues in use of chrysotile in manufacture of chrysotile cement sheets. In International Conference on Chrysotile Asbestos-Cement products, held at New Delhi, India from 10-11 November 2003. **(International)**
32. **Arti Shukla**, Trisha Flanders, Karen Lounsbury and Brooke T. Mossman. Asbestos-induced upregulation of MMPs is PKC delta dependent. Presented in 100<sup>th</sup> international conference of American Thoracic Society, held in Orlando, Florida, May 21-26, 2004. **Abstract published in Am J Resp. Crit. Care Med. 169, A857, 2004. (National)**
33. **Arti Shukla**, Joanna Gell, Trisha F Barrett, Maximillian MacPherson, Kelly Butnor, Sally Huber, Mercedes Rincon, Gerald Devis, Karen Lounsbury and Brooke Mossman. Decreased asbestos-induced pulmonary fibrosis in PKC delta knockout mice, a possible result of altered inflammatory profiles. Presented in Experimental Biology meeting 2005, held in San Diego, California from April 2-6, 2005. **Abstract published in The FASEB journal 19, A491, 2005. (National)**

34. Christy Ann Barlow, **Arti Shukla**, Brooke T. Mossman and Karen Lounsbury. Oxidant induction of CREB phosphorylation through calcium and ERK1/2 signaling in lung epithelial cells. Presented in Experimental Biology meeting 2005, held in San Diego, California from April 2-6, 2005. **Abstract published in The FASEB journal 19, A1507, 2005. (National)**
35. **Arti Shukla**, Joanna Gell, Trisha Barrett, Maximilian MacPherson, Kelly Butnor, Sally Huber, Mercedes Rincon, Gerald Davis, Karen Lounsbury and Brooke T. Mossman. The development of asbestos-associated pulmonary fibrosis is inhibited in protein kinase C delta knockout mice, a possible result of altered inflammatory profiles. Presented in 8<sup>th</sup> International meeting of Mechanisms of Action of Inhaled Fibers, Particles and Nanoparticles in Lung and Cardiovascular Disease, 2005, held in EPA Conference Center, Research Triangle Park, North Carolina from October 26-28, 2005. **(National)**
36. Christy A. Barlow, **Arti Shukla**, Brooke T. Mossman and Karen M. Lounsbury. Asbestos-mediated CREB phosphorylation is regulated by PKA independently of oxidants in lung epithelial cells. Presented in 8<sup>th</sup> International meeting of Mechanisms of Action of Inhaled Fibers, Particles and Nanoparticles in Lung and Cardiovascular Disease, 2005, held in EPA Conference Center, Research Triangle Park, North Carolina from October 26-28, 2005. **(National)**
37. Sylky Buder-Hoffmann, **Arti Shukla**, Trisha F. Barrett, Karen Lounsbury and Brooke T. Mossman. Asbestos-mediated activation of protein kinase D is protein kinase C delta dependent. Presented in 8<sup>th</sup> International meeting of Mechanisms of Action of Inhaled Fibers, Particles and Nanoparticles in Lung and Cardiovascular Disease, 2005, held in EPA Conference Center, Research Triangle Park, North Carolina from October 26-28, 2005. **(National)**
38. **Arti Shukla**, Trisha F. Barrett, Karen M. Lounsbury and Brooke T. Mossman. Matrix metalloproteinases regulation by asbestos in murine lung: Role of protein kinase C delta. Presented in Experimental Biology 2006 meeting, held at San Francisco, CA, April 2006. **Abstract published in The FASEB Journal, March 6, 20, 2006. (National)**
39. **Arti Shukla**, Trisha F. Barrett, Christy A. Barlow, Karen M. Lounsbury and Brooke T. Mossman. Cyclic AMP response binding protein regulation by asbestos. Presented at Platform session in mini symposia at Experimental Biology 2007 meeting held at Washington Convention Center, Washington, DC from April 28-May 2. **Abstract published in The FASEB journal, 21 (6), 2007. (National)**
40. **Arti Shukla**, Maximilian MacPherson and Brooke T. Mossman. Extracellular signal regulated kinases (ERK1/2) play an important role in migration, invasion and chemoresistance of human mesothelioma. Presented at AACR annual meeting, 2008, held at San Diego Convention center, San Diego, CA, 12-16 April 2008. **Abstract published in the proceedings of the meeting. (National)**
41. Hillegass J., **Arti Shukla** et al. Gene profiling of libby amphibole asbestos compared to crocidolite asbestos in human mesothelial cells. Presented at Society of Toxicology, March 2008. **(National)**

42. Juanita Vernooy, Nadja Drummen, Astrid Haegens, **Arti Shukla** et al. Stability of reference genes in five C57/Bl6 models of lung inflammation. Presented at European Respiratory Society Annual Congress 2008. **(International)**
43. **Arti Shukla** A positive correlation between mineral toxicity/pathogenicity and altered gene expression in human mesothelial cells. Presented at The 9<sup>th</sup> International Conference on Particles: Risks and Opportunities, 2-5 September 2008, Cape Town, South Africa. **(International)**
44. Hillegass J., **Arti Shukla**, Cheng K., Lathrop S., Brown A., Macpherson M., Landry C. and Mossman B.T. Use of amorphous silica nanoporous (APMS) beads for the targeted uptake and treatment of malignant mesothelioma. Presented at The 9<sup>th</sup> International Conference on Particles: Risks and Opportunities, 2-5 September 2008, Cape Town, South Africa. **(International)**
45. Hillegass J., **Arti Shukla**, MacPherson M., Alexeeva V., van der Vliet A., Gunter M. and Mossman B. T. Comparative analysis of gene expression profiles in LP9/TERT-1 human peritoneal mesothelial cells exposed to libby amphibole asbestos or crocidolite asbestos. Presented at The 9<sup>th</sup> International Conference on Particles: Risks and Opportunities, 2-5 September 2008, Cape Town, South Africa. **(International)**
46. **Arti Shukla**, Jedd Hillegass, Maximilian MacPherson, Stacie Beuchel and Brooke T. Mossman. Extracellular signal regulated kinase 2 (ERK2) plays a critical role in mesothelioma tumor growth. Presented at the 100<sup>th</sup> international AACR meeting, 18-22 April 2009, Denver, Colorado. **Abstract published in the proceedings of the meeting in Cancer Research. (National)**
47. Jeremy Steinbacher, Kai Cheng, Sherill Lathrop, **Arti Shukla**, Jedd Hillegass, Risto Kauppinen, Brooke Mossman and Christopher Landry. Mesoporous silica microparticles for biomedical applications: delivery of therapeutic agents and MRI contrast agents. Presented in Gordon Conference, June 2009. **(National)**
48. **Arti Shukla**. CREB-target genes in malignant mesothelioma. Vermont Genetics Network, Annual retreat, August 12, 2009, Doubletree Hotel, South Burlington, VT. **(Local)**
49. Jeremy L. Steinbacher, Sherill A. Lathrop, Kai Cheng, **Arti Shukla**, Jedd Hillegass, Brooke Mossman and Christopher C Landry. Nanoporous silica: surface modification strategies and use in biomedical applications, ACS 2009. **(National)**
50. **Arti Shukla**, Jedd Hillegass, Maximilian MacPherson, Stacie Beuschel, Sherill Lathrop, Nicholas Heintz and Brooke Mossman. Cell signaling and inflammatory pathways in asbestos-related diseases. OXI/Nitro stress, NY, Oct 2009. **(National)**
51. Hillegass J., **Arti Shukla**, Maximilian MacPherson, Stacie Beuschel, Sherill Lathrop, Chad Steele and Brooke Mossman. Identification of cytokines and growth factors associated with exposure of mesothelial cells to asbestos and progression of mesothelioma growth in mice. Society of Toxicology, March 2010. **(National)**
52. **Arti Shukla**, Jedd M Hillegass, Maximilian B. MacPherson, Stacie L. Beuschel, Nicholas Heintz, Pamela Vacek, Harvey Pass, Michele Carbone, Joseph R Testa, Brooke T Mossman. Inhibition of ERK1/2 can sensitize human malignant mesothelioma cells and tumors to

- doxorubicin. Presented at 101th, AACR meeting, 17-21 April 2010 at Washington DC. **Abstract 347; Cancer Research 2011, 70, 347-347. (National)**
53. **Arti Shukla**, Jedd Hillegass, Stacie Beuschel, Maximilian MacPherson, Harvey I Pass and Brooke T Mossman. Extracellular signal regulated kinase 5 (ERK5) in malignant mesothelioma. Presented at International MARF symposium, June 10-12, 2010, Washington DC. **(National)**
  54. **Arti Shukla**, Jedd Hillegass, Stacie Beuschel, Maximilian MacPherson, Harvey I Pass and Brooke T Mossman. CREB inhibition attenuates malignant mesothelioma tumor growth and drug resistance. AACR 2011, April 2-6, Orlando, Florida. **Published in proceedings of the meeting. (National)**
  55. **Shukla A**, Hillegass JM, Beuschel SL, MacPherson MB, Pass HI, and Mossman BT: Extracellular signal regulated kinase 5 (ERK5) in malignant mesothelioma. Mesothelioma Applied Research Foundation (MARF), International Symposium on Malignant Mesothelioma 2010, Washington DC, June 10-12, 2010 **(National)**
  56. **Shukla A**: Targeting signaling pathways to treat mesothelioma. Environmental Pathology and Carcinogenesis Seminar series, University of Vermont College of Medicine UVM, March 14, 2011 **(local)**
  57. **Shukla A**: CREB inhibition attenuates malignant mesothelioma tumor growth and drug resistance. American Association for Cancer Research (AACR), Orlando, FL (abstract published in meeting proceedings, Cancer Research), April 2-6, 2011 **(National)**
  58. **Shukla A**: ERK5: A potential target for mesothelioma therapy. Presented in International symposium on malignant mesothelioma. Mesothelioma Applied Research Foundation (MARF), International Symposium on Malignant Mesothelioma 2011, Washington, DC, June 25, 2011. **(National)**
  59. Newick K, Cunniff B, Held P, **Shukla A**, Pass H, Butnor K, Kundu K, Murthy N, Mossman B, and Heintz N: Targeting redox homeostasis in malignant mesothelioma. FRBM 51:s127, 2011. **Abstract published in FRBM. (National)**
  60. **Shukla A**, Miller JM, Hillegass JM, MacPherson MB, Beuschel SL, Pass HI, and Mossman BT: Role of NLRP3 inflammasome in the development and drug resistance of malignant mesothelioma. Presented at AACR annual meeting in Chicago, March 31-April 4, 2012; **Abstract published in Cancer Res 72(Suppl 8), 5461, 2012. (National)**
  61. **Shukla A**: NLRP3 inflammasome plays a significant role in the development and drug resistance of malignant mesothelioma. Oral Presentation at 11<sup>th</sup> International Conference of the International Mesothelioma Interest Group (iMig). **Abstract published in meeting proceedings**, September 11-14, 2012. **(National)**.
  62. Mossman BT and **Shukla A**: ERK Signaling and Mesothelioma: Oral Presentation at 11<sup>th</sup> International Conference of the International Mesothelioma Interest Group (iMig). **Abstract published in meeting proceedings**, September 11-14, 2012 **(National)**
  63. Miller JM, Macpherson MB, Beuschel SL, Sayan M, Mossman BT and **Shukla A**: Curcumin kills malignant mesothelioma cells by pyroptosis. Poster Presentation at 11<sup>th</sup> International

Conference of the International Mesothelioma Interest Group (iMig). **Abstract published in meeting proceedings**, September 11-14, 2012. **(National)**

64. **Shukla A**: Current Concepts of Causation of Mesothelioma by Amphibole Asbestos and Erionite; (abstract published in GSA Abstracts), vol. 45 no. 1), Oral presentation in Geologic Society of America, Northeastern Section Meeting, Bretton Woods, NH, March 18-20, 2013. **(National)**
65. **Shukla A et al.**: ERK5 in pathogenesis of mesothelioma. Presented at AACR Annual Meeting (abstract # 4315, published in Cancer Research, 2013, 73, 4315-4315), Washington, DC, April 6-10, 2013. **(National)**
66. **Shukla A**: Mesothelioma and Inflammasomes: Is there a connection? Vermont Lung Center, UVM, April 30, 2013. **(Local )**
67. Brooke Mossman, Sonali Herath, Eric Taylor, Steven Lower, Julie Dragon, Jeff Bond, Ann Wylie and **Arti Shukla**: New data on how asbestos fibers interact with cells to trigger extracellular signal-regulated protein kinase, i.e. ERK, pathways critical to toxicity and diseases. Presented in 10<sup>th</sup> International Meeting on Particle Toxicology in Dusseldorf, Germany (abstract published in the proceedings). June 2013. **(International)**.
68. Joyce Thompson and **Arti Shukla**: Asbestos-induced inflammasome regulation by TXNIP. Presented in an inflammasome conference at Boston University, June 24-25, 2013. **(National)**
69. **Arti Shukla**, Mesothelioma, a brief research review, VCC/MMM presentation, September 23, 2013. **(local)**
70. **Arti Shukla**, Differential susceptibility of pleural and peritoneal mesothelial cells to asbestos exposure as assessed by Massive Parallel Sequencing, December 2, 2013. **(Local)**
71. **Arti Shukla**, Mesothelioma/lung cancer, VCC Journal club, Jan 3, 2014. **(Local)**
72. **Arti Shukla**, Manipulating inflammasomes for mesothelioma treatment, presented in mesothelioma symposium, Honolulu, Hawaii, Feb 21-22, 2014 **(National)**.
73. **Arti Shukla**, Role of inflammasomes in malignant mesotheliomas. Presented in the Society of Toxicology workshop entitled- New Concerns and New Science Addressing Environmental Asbestos Exposures, Phoenix, Arizona, March 23-27, 2014 **(National)**.
74. **Arti Shukla**, Modulation of NLRP3 by chemotherapeutics: Potential application in mesothelioma treatment. American Association of Cancer Research, 2014, April 5-9, San Diego CA. Abstract 3183: **Abstract published in Cancer Research, 2014, 74, 3183. (National)**.
75. **Arti Shukla**, Pharmacology seminar, September 18, 2015 **(Invited, local)**.
76. Tim Hunter<sup>1</sup>, Meghann Palermo<sup>1</sup>, Heather Driscoll<sup>2</sup>, Scott Tighe<sup>1</sup>, Julie Dragon<sup>1</sup>, Jeff Bond<sup>1</sup>, **Arti Shukla**<sup>1</sup>, Mahesh Vangala<sup>2</sup>, James Vincent. Expression profiling smackdown: Human Transcriptome Array HTA 2.0 vs. RNA-Seq. Presented in, New Mexico, March 2014.

**Abstract published in Journal of Biomolecular Techniques, 2014; 25, s20-s21 (National).**

77. Julie Dragon, Joyce Thompson, Maximilian MacPherson and **Arti Shukla**. Differential susceptibility of pleural and peritoneal mesothelial cells to asbestos. Beyond the Genome: Cancer genomics, 8-10 Oct, Harvard Medical School. **(National)**
78. **Arti Shukla**, Joyce Thompson, Alan Leggett, Anurag Shukla, Maximilian MacPherson and Stacie Beuschel. ERK5 inhibitor XMD8-92 for malignant mesothelioma treatment: a preclinical study. American Association of Cancer Research, 2015, April 18-22, doi: 10.1158/1538-7445.AM2015-38 Cancer Res August 1, **2015** 75; 38 Abstract 38. **(National)**
79. Joyce K. Thompson, Maximilian B. MacPherson, Stacie L. Beuschel, and **Arti Shukla**. Inflammasomes: fanning the flames of malignant mesothelioma initiation. American Association of Cancer Research, 2015, April 18-2. **Abstract published in Cancer Research** August 1, **2015** 75; 3164, doi: 10.1158/1538-7445.AM2015-3164.
80. Phillip Munson, Joyce Thompson, Maximilian MacPherson, Hector Peinado and **Arti Shukla**. Circulating Biomarkers World Congress 2016, March 21-22, Boston. Exosomes, Circulating Nucleic Acids, Circulating Proteins, CTCs and Liquid Biopsies.
81. **Arti Shukla**, Phillip Munson, Joyce Thompson, Julie Dragon, Maximilian MacPherson and Hector Peinado. Unique pleural vs. peritoneal mesothelioma exosomal signature: does mesothelial cell susceptibility to asbestos matter? American Association of Cancer Research, 2016, April 16-20. Abstract 3892: **Abstract published in Cancer Research** 07/2016; 76 (14 Supplement). DOI: 10.1158/1538-7445.AM2016-3892
82. Joyce Thompson, Jill Miller, Maximilian MacPherson and **Arti Shukla**. The role of TFPI2 and FGF2 in asbestos-induced mesothelial to fibroblastic transition. American Association of Cancer Research, 2016, April 16-20. Abstract 4046, **Abstract published in Cancer Research** 07/2016; 76 (14 Supplement). DOI: 10.1158/1538-7445.AM2016-3892
83. Yuwaraj Kadariya, Craig Menges, Jacqueline Talarchek, Kathy Q. Cai, Andres J. Klein-Szanto, Ralph A. Pietrofesa, Melpo Christofidou-Solomidou, Mitchell Cheung, Brooke T. Mossman, **Arti Shukla**, and Joseph R. Testa. The NALP3 inflammasome and IL-1B signaling link asbestos-induced inflammation with the development of malignant mesothelioma. American Association of Cancer Research, 2016, April 16-20. Abstract 842. **Abstract published in Cancer Research** 07/2016; 76(14 Supplement). DOI:10.1158/1538-7445.AM2016-842
84. Phillip Munson, Nicholas Farina and **Arti Shukla**. Exosomal miRNA: A new approach to mesothelioma biomarkers. UVMCC Clinical and Translational Symposium, April 29, 2016.
85. Phillip Munson, Elizabeth M. Hall, Nicholas H. Farina, Harvey I. Pass and **Arti Shukla**. Mesothelioma exosomes as potential new cancer therapy. Presented at American Association of Cancer Research, 2019, April. Published in, Cancer Res 2019;79 (13 Suppl): Abstract no. 2743.
86. **Arti Shukla** Effect of per-fluorinated substances (PFAS) on mouse lung-gene expression profile. Presented at Pathology department Research Day, September 14, 2022.



## INVITED PRESENTATIONS

### Local/Regional

<b>Years</b>	<b>Host Organization “Title of Talk”</b>	<b>City, State</b>
2011	Environmental Pathology and Carcinogenesis seminar at the University of Vermont College of Medicine “Targeting signaling pathways to treat mesothelioma”	Burlington, VT
2013	Geologic Society of America, Northeastern Section Meeting “Current Concepts of Causation of Mesothelioma by Amphibole Asbestos and Erionite”	Bretton Woods, NH
2013	Vermont Lung Center, The University of Vermont College of Medicine “Mesothelioma and Inflammasomes: Is there a connection?”	Burlington, VT
2013	Vermont Cancer Center, Molecular Mechanism Meeting, The University of Vermont College of Medicine “Mesothelioma, a brief research review”	Burlington, VT
2013	Environmental Pathology and Carcinogenesis Seminar, The University of Vermont College of Medicine “Differential susceptibility of pleural and peritoneal mesothelial cells to asbestos exposure as assessed by Massive Parallel Sequencing”	Burlington, VT
2013	Vermont Cancer Center Journal Club, The University of Vermont College of Medicine “Mesothelioma/lung cancer”	Burlington, VT
2015	Department of Pharmacology Seminar, The University of Vermont College of Medicine “Malignant mesothelioma: development to therapy”	Burlington, VT
2015	UVM Cancer Center Grand Rounds, The University of Vermont College of Medicine “Potential new targets for malignant mesothelioma therapy”	Burlington, VT
2015	Pathology Grand Rounds, The University of Vermont College of Medicine “Mesothelioma: Biology to therapy”	Burlington, VT
2015	Department of Biochemistry Seminar, The University of Vermont College of Medicine “Mesothelioma development and therapy: Where do inflammasomes fit in”	Burlington, VT



**National**

<b>Years</b>	<b>Host Organization "Title of Talk"</b>	<b>City, State</b>
2002	9 <sup>th</sup> Annual Meeting of the Oxygen Society "PKC delta selectively regulates asbestos-induced fra-1 transcription"	San Antonio, TX
2014	Mesothelioma Symposium, University of Hawaii Cancer Center "Manipulating inflammasomes for mesothelioma treatment"	Honolulu, HI
2014	Society of Toxicology Workshop-New Concerns and New Science Addressing Environmental Asbestos Exposures "Role of inflammasomes in malignant mesotheliomas"	Phoenix, AZ
2015	University of Rochester Environmental Health Science Center's Seminar Series "Inflammasomes in Asbestos-Induced Mesothelial Cell Pathogenesis"	Rochester, NY
2015	Department of Pharmaceutical Sciences, University of West Virginia "Inflammasomes in development and therapy of mesothelioma"	Morgantown, WV
2015	Molecular Toxicology Gordon Conference "Inflammasomes in fiber-induced mesothelial to fibroblastic transition (MFT)"	Andover, NH
2015	Center of Excellence in Environmental Toxicology/Super Fund Program, University of Pennsylvania "Mesothelial cell pathogenesis by asbestos: Role of inflammasomes"	Philadelphia, PA
2017	Mesothelioma Applied Research Foundation (MARF) "Inflammasomes in mesothelioma: Is ERK5 a connecting link?"	Bethesda, MA
2017	NIEHS Workshop on Health Effects of Asbestos "Exosomal protein content: possible biomarkers of asbestos exposure"	Burlington, VT
2017	ENACT: Emerging Nanotechnology Applications for Cancer Therapy, The University of Oklahoma Health Sciences Center "Exosomes in mesothelioma biology"	Oklahoma City, OK
2019	Annual Mike Hasson Lectureship, Oregon Health Science University "Exosomes and Mesothelioma. Is there a hope?"	Portland, OR
2020 Oct	Monticello II Conference (to be rescheduled due to Corona) (postponed due to COVID-19)	Charlottesville, Virginia

---

## **International**

<b>Years</b>	<b>Host Organization “Title of Talk”</b>	<b>City, Country</b>
2003	International Conference on Chrysotile Asbestos-Cement products “Health issues in use of chrysotile in manufacture of chrysotile cement sheets”	New Delhi, India
2008	The 9 <sup>th</sup> International Conference on Particles: Risks and Opportunities “A positive correlation between mineral toxicity/pathogenicity and altered gene expression in human mesothelial cells”	Cape Town, South Africa
2010	Mesothelioma Applied Research Foundation (MARF), International Symposium on Malignant Mesothelioma 2010 “Extracellular signal regulated kinase 5 (ERK5) in malignant mesothelioma”	Washington, DC
2011	Mesothelioma Applied Research Foundation (MARF), International Symposium on Malignant Mesothelioma 2011 “ERK5: A potential target for mesothelioma therapy”	Washington, DC
2012	11 <sup>th</sup> International Conference of the International Mesothelioma Interest Group (iMig) “NLRP3 inflammasome plays a significant role in the development and drug resistance of malignant mesothelioma”	Boston, MA
2016	11 <sup>th</sup> International Particle Toxicology Conference “Targeting FGF2/TFPI2 signaling as a potential key to unlocking asbestos-induced mesothelial to fibroblastic transition”	Singapore
2016	11 <sup>th</sup> International Particle Toxicology Conference “Asbestos and carbon nanotube-induced mesothelial cell pathogenesis involves inflammasome activation via unfolded protein response”	Singapore
2017	7 <sup>th</sup> International Symposium on Malignant Pleural Mesothelioma, UCLA Luskin Center “Inflammasome Modulation by Chemotherapeutics in Mesothelioma: Is This a New Possibility?”	Los Angeles, CA

## **Summary of Scholarly Activities**

Obtained multiple extramural (MARF, 2 NIH, DoD) and intramural grants and established a successful independent research program. Highly recognized by mesothelioma/lung cancer program, as evident by grant review and chair invitations from DoD, NIH and European agencies. Also nationally/internationally recognized in the field and often invited to give talk and/or chair the session in prestigious meetings including Gordon Research Conference/ Mike Hasson lectureship. Published total 105 articles in high impact factor journals/total citations 7685. My exosome research was highlighted by DoD in their annual report, 2016 and again in 2018. On July 31, 2017, I co-organized, NIEHS asbestos health-effect, workshop. Won prestigious awards for my work in cancer (SAACAR, MJ Hassan Lectureship). My work was featured on Asbestos.com twice (2018, 2022). Total 86 research presentations from my work were made in different societies (AACR, ATS, FRBM, EB etc.). Many of these abstracts were published in society-related journals.